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ABSTRACT 
 
AIM :   
             The aim of the study is to find, whether the presence of systemic 
autoimmune diseases in an individual is a risk factor for the development of 
Periodontal disease. 
 
MATERIALS AND METHODS: 
               A sample of 253 patients with Systemic autoimmune diseases, 
attending the Rheumatology department of Madras Medical College and 
Government General Hospital, Chennai-3 and 262 patients without Systemic 
autoimmune diseases, attending the outpatient department of the Tamilnadu 
Government Dental College and Hospital, Chennai -3 constituted the case and 
control groups. Age, gender and Oral hygiene status matching was done. Oral 
hygiene status was assessed using Oral Hygiene Index original and Periodontal 
status was assessed using Community Periodontal Index in association with 
Loss of Attachment Index. Statistical analysis was done using SPSS version 15.  
 
RESULTS  
              Results showed 99.2% and 73.9% prevalence of gingivitis and 
periodontitis respectivelyin the case  group as compared to 85.5% and 14.9% in  
 
 
 the control group. Results also showed no linear relationship between oral 
hygiene scores (OHI-original) and prevalence of periodontitis (CPI & LOA 
scores) in case group.  
 
CONCLUSION 
              Patients suffering from systemic autoimmune diseases showed more 
prevalence of periodontal diseases  irrespective of oral hygiene scores. Hence 
one may assume that the presence of systemic autoimmune diseases in a patient 
leads to risk in development of periodontal disease. Conversely in patients with 
periodontal disease with no local factors, one must rule out any undiagnosed 
systemic autoimmune diseases. 
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INTRODUCTION 
                      The immune system protects the host against infection 
specifically by recognizing and eliminating foreign agents from the body. The 
immune system does not normally respond to self antigens1. The ability to 
discriminate between self antigens and non-self antigens is tolerance.2,3  
Immunologic tolerance is a state in which the individual is incapable of 
developing an immune response to a specific antigen which can be achieved by 
various routes4. 
                             
                      Autoimmune diseases comprise a group of disorders where there 
is nothing apparently in common other than an exaggerated immune response 
to one or more of the self antigens.5 The term autoimmune diseases refer to a 
disorder in which there is evidence of an immune response against self. The 
functional abnormality in immunologic self- tolerance directly leads to the 
development of autoimmune diseases.6 A common feature of all autoimmune 
diseases is the presence of auto-antibodies and inflammation including 
mononuclear phagocytes, autoreactive T lymphocytes and plasma cells 
(autoantibody producing B cells). 
 
                    Autoimmune diseases are classified into7,  
i) Organ specific autoimmune diseases and  
ii) Non organ specific (Sytemic) autoimmune diseases. 
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                         Major pathogenic role in many autoimmune diseases lies 
behind the damage induced by cells of the immune system against own body 
cells. The predominant infiltrating cells in autoimmune diseases include 
phagocytic macrophages, neutrophils, self-reactive Cluster of 
differentiation(CD) 4+ T helper cells and self-reactive CD8+ cytolytic T cells, 
with smaller numbers of natural killer(NK) cells, mast cells and dendritic cells. 
Immune cells damage tissues directly by killing cells or indirectly by releasing 
cytotoxic cytokines, prostaglandins(PG), reactive nitrogen or oxygen 
intermediates.7,8 Pathogenic mechanism common to autoimmune diseases is the 
increased production of the cytokines, such as Tumour necrosis factor (TNF) 
and Interleukin factor(IL) -1b.7 
 
                       Periodontal disease is characterized by a chronic infection and 
inflammation in the periodontal tissue leading to the destruction of the bone 
surrounding the teeth and ultimately to dental loss.9 Periodontal disease which 
includes gingivitis and periodontitis,10 is one of the most common chronic 
disorders of infectious origin known in humans with a high prevalence in 
adults. The paradigm of immune responses is consistent with the specific 
plaque hypothesis, current concepts in immunology and the classic clinical and 
histologic observations.  
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                      Pathogenic mechanism common to autoimmune diseases7 and 
Periodontal disease11 is the increased production of the cytokines TNF and IL-
1b. Susceptible patients exhibit an abnormal immune mediated inflammatory 
response.12 In rheumatoid arthritis there may be increased propensity to 
overproduce these inflammatory mediators which could possibly lead to 
increased periodontal destruction.13 In both rheumatoid arthritis (a type of 
autoimmune diseases) and periodontal diseases, are associated with destruction 
of bone, mediated by inflammatory cytokines such as IL-1, TNF and PGE2.13 
                     
                      Immune mechanism both for systemic autoimmune diseases and 
periodontal disease shares some common pathway in their effects. Hence this 
study has been done to prove the correlation between the above two entities. 
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AIMS AND OBJECTIVES 
AIM:  
             The aim of the study is to find, whether the presence of systemic 
autoimmune diseases in an individual is a risk factor for the development of 
periodontal diseases of patients. 
 
OBJECTIVES: 
¾ To assess the Oral hygiene status of patients with and without Systemic 
autoimmune diseases using Oral Hygiene Index original by Greene and 
Vermillon in 1960. 
¾ To assess the periodontal conditions of patients with and without 
Systemic autoimmune diseases using Community Periodontal Index 
with Loss of Attachment by WHO in 1997. 
¾ Compare prevalence of periodontal diseases between patients with and 
without Systemic autoimmune diseases.   
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REVIEW OF LITERATURE 
 
Systemic autoimmune diseases 
         Systemic autoimmune diseases are a complex, heterogeneous 
group of diseases in which the immune system targets a diverse, but highly 
specific group of intracellular autoantigens14. Systemic autoimmune diseases 
are generally characterized by the production of autoantibodies that directed 
against intracellular antigens15 and recognize a diverse array of cytoplasmic 
and nuclear antigens16. In systemic autoimmune diseases, individuals develop 
auto-antibodies directed against a variety of cellular components. It is 
remarkable that a particular set of autoantibody specificities is associated with 
each disease17. 
 
Periodontal disease 
                    Periodontal disease include pathological conditions of the 
supporting structures of the teeth i.e., gingiva, alveolar bone, periodontal 
ligament and cementum. Progression of periodontal disease is considered to be 
a continuous process rather than a episodic pattern. It is considered to be a 
continuous process with acute periods of exacerbation18. 
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Immune mechanism in systemic autoimmune diseases 
         Kazutaka Shibatomi et al., in 200119 evaluated the relationship 
between  serum  cytokine  levels  and  peripheral  blood  Natural killer cell 
number  in  58 Japanese patients with systemic autoimmune diseases, 
compared with 33 healthy controls  and  examined  the  role  of  IL-18 in 
human NK cell death in  vitro.  Data  revealed  that  increased  levels  of  
cytokines  correlate  with reduced numbers of NK cells in these patients. High 
levels of IL-18 and IL-15 are associated with the decreased number of NK cells 
that is observed in patients with systemic autoimmune diseases. 
           
         Dennis M Klinman and Alfred  D.Steinberg in 198720 
conducted a animal study in mice and  suggested that systemic autoimmunity 
results from generalized polyclonal activation and not from specific stimulation 
of autoreactive clones. 
 
Immune mechanism in periodontal disease 
                     Lappin DF et al., in 200321 evaluated from a study conducted 
using  tissue  biopsies from 12 periodontitis patients that overall the mucosal 
immune response plays a minor role and acts on superficial tissues only. The 
systemic immune plays a predominant  role in the disease mechanism.  It is 
well known  that   there   is  a   shift   from  a   predominantly   T-cell  to   B-
cell  lesion  in  the  
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progression from health to gingivitis and periodontitis. Thus this shift occurs 
during the development of periodontal disease. 
                    
                     Denis F Kinane et al., in 199922 conducted a study using tissue 
biopsies of 9 adult periodontitis patients and concluded that immune 
mechanisms involved in the pathogenesis of periodontitis may involve features 
of both the mucosal and systemic immune systems, dependent on tissue 
location.  
 
Rheumatoid arthritis and Periodontal disease: 
         Eduardo de Paula Ishi et al., in 200813, performed a study among 
29 rheumatoid arthritis patients with 22 healthy controls to find the association 
between periodontitis and rheumatoid arthritis and the results showed that, the  
test  group (patients with rheumatoid  arthritis)  presented a higher frequency of 
sites with attachment loss greater  than or equal to 5 mm than the control group. 
Rheumatoid arthritis patients might be predisposed to periodontitis since they 
presents a higher risk for infections (due to medication-induced 
immunosuppression) and for inflammatory-mediated destruction (due to an 
unbalanced cytokine expression profile). 
 
        G.A.Scardina and P.Messina in 200723 conducted a study to 
investigate  the  differences  in  periodontal  microcirculation  between 30  
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healthy subjects and 30 rheumatoid arthritis patients. The study showed that 
capillary alterations in patients suffering from rheumatoid arthritis occur in 
periodontal microcirculation;  such  evidence  could  be  extremely  important,  
suggesting that microvascular periodontal alterations may play a crucial part in 
the complex activity associated with periodontal disease in arthritis patients. 
 
         Biyikoglu B. Buduneli et al., in 200624 studied 27 rheumatoid 
arthritis patients, 17 systemically healthy subjects with periodontal disease and 
17 systemically and periodontally healthy subjects, to  evaluate  if  co-existence  
of  periodontitis and rheumatoid arthritis had an additional effect on  the  
severity  of  the two diseases and to evaluate the correlation between clinical 
situation and gingival crevicular fluid (GCF) levels of inflammatory mediators. 
The study suggested that, the coexistence of rheumatoid arthritis and 
periodontitis does not seem to affect clinical periodontal findings or systemic 
markers of rheumatoid arthritis. Similar inflammatory mediator levels in 
rheumatoid arthritis and periodontal disease groups, despite the long-term 
usage of corticosteroids, non-steroidal anti-inflammatory drugs, suggest that 
rheumatoid arthritis patients may have a propensity to overproduce these 
inflammatory mediators. 
 
           Anne Havemose-Poulsen el al., in 200625 conducted a study on 
18 subjects   of    localized    aggressive    periodontitis,  27  subjects   of    
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generalised aggressive periodontitis, 10 subjects of juvenile idiopathic arthritis, 
23 subjects of  rheumatoid arthritis and 25 healthy subjects to elucidate whether 
all subjects share periodontal  and  hematological   characteristics  
distinguishing  them from healthy individuals. The results suggested that 
patients with rheumatoid arthritis may acquire periodontal destruction early in 
the course of disease. Patients   with   generalized aggressive periodontitis may 
present with elevated levels of traditional markers of inflammation similar to 
patients with rheumatoid arthritis and juvenile idiopathic arthritis. Thus, 
similarities in periodontal and hematological variables were seen in individuals 
with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid 
arthritis, distinguishing them from controls. 
   
          Lagervall M Jansson et al., in 200326 studied the population of 
1006 subjects to explore possible relationships between general health and 
periodontal disease severity. The results showed no significant associations 
between investigated systemic disorders and periodontal disease severity were 
found if the relative frequency of deep periodontal pockets was used as the 
clinical parameter for periodontal disease severity. However, cardiovascular 
disease, diabetes and rheumatoid disease were found to be significantly 
correlated to number of lost teeth, which may represent one aspect of 
periodontal health. This result held true in nonsmokers only. 
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          F.B.Mercado et al., in 200127 studied 65 subjects with 
rheumatoid  arthritis  and  healthy  subjects  corresponding to it, to determine 
the extent of their periodontal  disease  and  correlate  this  with  various  
indicators  of   rheumatoid arthritis. The results showed that the relationship 
between disease experience of rheumatoid arthritis and periodontitis can be 
demonstrated by assessing a defined group of individuals diagnosed with 
rheumatoid arthritis using standard clinical and laboratory parameters. Indeed 
those individuals who have moderate to severe rheumatoid arthritis are also 
very likely to suffer from moderate to severe periodontitis. 
 
          Fatma Yesim Bozkurt et al in 200028 conducted a study in 15 
patients with rheumatoid arthritis and adult periodontitis, 15 patients with adult 
periodontitis and 15 healthy subjects to determine and compare IL-6  levels in 
GCF in patients with rheumatoid arthritis and adult periodontitis. The results 
showed no significant difference detected in the clinical parameter except 
plaque index. There was only strong negative correlation between GCF and IL 
-6 levels in the rheumatoid arthritis group. 
 
Systemic lupus erythematosus and Periodontal disease: 
          Tetsuo Kobayashi et al., in 200329 studied 42 systemic lupus 
erythematosus  (SLE)  patients   with   periodontitis,   18   SLE   patients   
without periodontitis, 42 healthy subjects with periodontitis and 42 healthy  
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subjects without periodontitis to evaluate whether Fc domain of 
Immunoglobulin G (FcγR) gene polymorphisms are associated  with  
periodontitis  risk  in SLE patients. It had been documented that the low ligand 
binding Fcγ RIIa- R131allele was associated with periodontitis risk in SLE 
patients. Identification of FcγR genotypes might be reliable strategy for 
predicting the onset of periodontitis in SLE patients. 
 
                    Ernesto Nova et al., in 199930 conducted a study on 30 patients 
with SLE, 30 patients with rheumatoid arthritis and 20 healthy subjects. The 
results showed a marked difference in the number and distribution of anti-
neutrophilic cytoplasmic antibodies (ANCA) with respect to periodontitis 
between rheumatoid  
arthritis and SLE was found. hyperresponsiveness of  B cells and  polyclonal B  
activation  to periodontopathic bacteria in SLE might be accountable for the 
high numbers of ANCA and the close association observed between those 
autoantibodies and periodontitis in SLE. 
 
Sjogrens syndrome and Periodontal disease: 
         Jacques Olivier Pers et al., in 200531 studied 15 patients of 
primary sjogrens syndrome and 15 xerostomia patients as control group to 
correlate the periodontal status of primary sjogrens syndrome patients with 
salivary B cell activating F factor (BAFF) levels. The  study   suggested  that   
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the  findings  of  bone  resorption  in  primary sjogrens syndrome are similar to 
that observed in patients with rheumatoid arthritis. They also suggested that the 
known effect of B cells in periodontitis would be partly mediated by salivary 
BAFF in patients with primary sjogrens syndrome. 
 
           Kuru.B et al., in 200232  conducted a study consisting of 8 
primary sjogrens syndrome patients, 10 secondary sjogrens syndrome patients 
and 11 healthy subjects as control group to evaluate whether the periodontal 
status of sjogrens syndrome patients in terms of clinical and microbiological 
parameters differ from systemically healthy individuals. The results suggested 
that there was no significant differences could be detected in either clinical or 
microbiological parameters of primary or secondary sjogrens syndrome 
patients compared with that of control subjects. Thus results  of  the  study  
supported  the  notion  status;  microbiology; peptidase activity; polymerase 
chain reaction that the periodontal status of patients with sjogrens syndrome do 
not differ from systemically healthy age- and gender-matched controls. 
 
          Boutsi et al., in 200033 performed a study on 24 sjogrens 
syndrome patients, 27 other autoimmune disease patients and 29 subjects with 
subjective feeling of xerostomia to evaluate the dental and periodontal 
condition and influence  of  reduced salivary flow in the periodontal tissues. 
The results showed no significant difference could be detected concerning the  
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dental and periodontal status of Sjogrens syndrome patients, compared with 
that of other patients. 
 
Systemic sclerosis and periodontal disease 
                   G.A.Scardina et al., in 200534 conducted a study in 15 patients 
with  systemic  sclerosis  and  15  healthy  patients  to  observe differences in 
periodontal  microcirculation  between  healthy  patients  and  patients   with 
systemic sclerosis. The results showed the microvascular changes in systemic 
sclerosis compared to healthy patients. Capillary alterations in patients with 
systemic sclerosis are also occur in periodontal mucosa microcirculation.             
 
Spondyloarthropathy and periodontal disease 
                       N.Pischon et al., in 201035, studied 48 patients with ankylosing 
spondylitis  and 48 healthy controls to determine association between 
ankylosing spondylitis and periodontal disease. The results showed that there 
was 6.81 fold increased odds of periodontal disease in patients with ankylosing 
spondylitis as compared with healthy controls.  
 
Inflammatory myopathies and periodontal disease 
                       Krisztina Marton et al., in 200536 performed a complete 
analysis of   orofacial  abnormalities in 34 patients with polymyositis and  
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dermatomyositis The results could not demonstrate any difference in the 
severity of periodontal destruction between patients and healthy controls. 
 
Antiphospholipid syndrome and periodontal disease 
                       Schenkein.H.A et al., in 200737 conducted a study on 190 
patients with generalized aggressive or chronic periodontitis and 90 healthy 
subjects. It showed elevated serum levels of vascular inflammation markers in 
patients with higher anti-cardiolipin (anti-CL) autoantibodies (anti-
phospholipid antibodies) which are higher in antiphospholipid syndrome and 
SLE patients.    
 
Vasculitis and periodontal disease 
                    Haviye Celenligil- Nazliel et al in 199938 studied about 
periodontal condition of 33 patients with Behcet’s disease and 15 health 
subjects. The results showed values of probing depth, plaque index, periodontal 
index and sulcular bleeding index were more in patients with Behcet’s disease 
than healthy subjects. 
 
                     There were no studies that directly enumerate the periodontal 
status  of patients with adult onset still’s disease and mixed connective tissue 
disease.  
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MATERIALS AND METHODS 
STUDY TYPE:    
                     It is a case control study.    
       a) Case group:  
                     Case group constituted 253 patients with systemic autoimmune 
diseases attending the Rheumatology department of Government General 
Hospital, Chennai-3. 
       b) Control group: 
         Control group constituted 262 patients without systemic 
autoimmune diseases matched for age, gender and Oral Hygiene Index (OHI) 
scores attending the outpatient department of the Tamilnadu Government 
Dental College & Hospital, Chennai-3. 
 
INCLUSION CRITERIA: 
            1) Subjects with non organ specific autoimmune diseases for case 
group. 
            2) Subjects without systemic autoimmune diseases for control group. 
             
EXCLUSION CRITERIA: 
           1) Organ specific autoimmune diseases are excluded. 
           2)  Patients with any other systemic diseases. 
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STUDY PROTOCOL  
¾ A complete case history was recorded for both groups. Written informed 
consent obtained. 
¾ Age (Subgroups: 15-24, 25-34, 35-44, 45-54, 55-64, and 65-74 years), 
gender (Subgroups: Male and female) and Oral hygiene scores 
(Subgroups: OHI-original score 0-4.0, 4.1-8.0 and 8.1-12.0) matching 
has been performed between case group and control group.  
¾ Patients already diagnosed with systemic autoimmune diseases at Govt. 
General Hospital, Chennai -3 (after history, clinical examination, 
diagnostic tests and markers) contributed the case group. 
¾ Patients without systemic autoimmune diseases attending the outpatient 
department of Tamilnadu Govt. Dental College & Hospital, Chennai -3 
contributed the control group after matched for age, gender and OHI 
scores. 
¾ Oral hygiene status of patients with and without systemic autoimmune 
diseases (case group and control group) were assessed using Oral 
Hygiene Index (OHI)39 original by Greene and Vermillion in 1960 
criteria. 
¾ Periodontal condition of patients were assessed using Community 
Periodontal Index (CPI) 40  with Loss of Attachment (LOA) by WHO 
1997.  
¾ Values were tabulated and Scores were compared between case group 
and control group to analyze the prevalence of periodontal disease.   
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                                        ARMAMENTARIUM USED 
                                         Universal precautions taken. 
                                         Examination was done using 
• Plain mouth mirror 
• Explorer 
• Tweezer 
• CPI  Probe 
• Cotton 
 
         
                 PHOTOGRAPH -1                              PHOTOGRAPH - 2 
                                                                     Measuring probing depth   
                 Armamentarium                                      using CPI probe  
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TABLE -1 
List of organ specific autoimmune diseases41 
Organ Autoimmune disease 
Thyroid Autoimmune thyroiditis, Primary myxedema, Thyrotoxicosis, 
Grave's disease 
Parathyroid Parathyroid insufficiency 
Pancreas 
Insulin resistant diabetes associated with acanthosis nigricans, 
Insulin resistant diabetes with ataxia telengiectasia, Insulin 
dependent diabetes.
Adrenals Addison’s Disease 
Gonads Premature ovarian failure 
Gastrointestine 
Atropic gastritis, Ulcerative colitis, Crohn’s disease, 
Autoimmune chronic active hepatitis,  Primary biliary 
cirrhosis, Pernicious anaemia
Skin Pemphigus Vulgaris, Bullous pemphigoid, Cicatrical 
pemphigoid, Dermatitis Herpetiformis
Others Myasthemia gravis, Good pasteur's syndrome, Autoimmune 
heamolytic anaemia, Demyelinating herpetiformis 
 
TABLE - 2 
            List of systemic autoimmune diseases  
             (non –organ specific) 41,42,43 
S.No Systemic autoimmune diseases 
1 Rheumatoid arthritis
2 Systemic lupus erythematosus
3 Systemic sclerosis 
4 Sjogrens syndrome
5 Vasculitis 
6 
Inflammatory myopathies 
a. Dermatomyositis 
b. Polymyositis 
c. Inclusion body myositis
7 Spondyloarthropathy
8 Mixed connective tissue disease
9 Antiphospholipid syndrome
10 Adult onset still's disease
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TABLE - 3 
Revised criteria for the classification of rheumatoid arthritis – 198744 
S.No Criteria Definition 
1 Morning Stiffness 
Morning stiffness in and around the joints, lasting atleast 1 hour 
before maximal improvement.  
2 
Arthritis of 3 
or more joint 
areas 
At least 3 joint areas simultaneously have had soft tissue 
swelling or fluid (not bony growth alone ) observed by a 
physician. The 14 possible areas are right or left Proximal 
Interphalangeal (PIP), Meta Carpophalangeal (MCP), Wrist, 
Elbow, Knee, Ankle and Meta Tarsophalangeal (MTP) joints. 
3 Arthritis of hand joints Atleast 1 area swollen in a wrist, MCP or PIP joint.  
4 Symmetric Arthritis 
Simultaneous bilateral involvement of same joint areas on both 
sides of the body.(Bilateral involvement of PIPs , MCPs or 
MTPsis acceptable without acceptable symmetry).  
5 Rheumatoid nodules 
Subcutaneous nodules, over bony prominences or extensor 
surfaces or in juxtaarticular regions, observed by physician. 
6 
Serum 
rheumatoid 
factor 
Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been positive in  
< 5% of normal control subjects.
7 Radiographic changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs which must include 
erosions or unequivocal bony decalcification localized in or 
most marked adjacent to the involved joints (osteoarthritis 
changes alone do not qualify). 
                       A patient shall be said to have Rheumatoid arthritis if he/she has satisfied 
at least 4 of these 7 criteria. Criteria 1 through 4 must have been present for atleast 6 
weeks. Patient with 2 clinical diagnosis are not excluded.
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TABLE - 4 
Revised criteria for the classification of systemic lupus erythematosus 
– 198245 
S.no Criteria Definition 
1 Malar Rash Fixed erythema flat or raised over the malar eminences tending to spare the nasolabial folds. 
2 Discoid Rash 
Erythematous raised patches with adherent keratotic 
scaling and follicular plugging, atropic scarring may 
occur in older lesions. 
3 Photosensitivity Skin rash as a result of unusual reaction to sunlight by patient history or physician observation. 
4 Oral Ulcers Oral or nasopharyngeal ulceration usually painless observed by a physician. 
5 Arthritis  
Nonerosive arthritis involving 2 or more peripheral 
joints charecterised by tenderness, swelling or 
effusion. 
6 Serositis 
a) Pleuritis  - convincing history of pleuritic pain 
or rub heard by a physician or evidence of 
pleural effusion.  ( OR) 
b) Pericarditis – documented by ECG or rub or 
evidence of pericardial effusion.  
7 Renal disorder 
a) persistent proteinuria greater than 0.5 grams 
per day or greater than 3+ if quantitation not 
performed. ( OR) 
b) Cellular casts – may be red cell, 
Haemoglobin, granular, tubular or mixed.  
8 Neurologic disorder 
a) seizures - in the absence of offending drugs or 
known metabolic derangements; e.g.uremia, 
ketoacidosis or electrolyte imbalance (OR) 
b) Psychosis – in the absence of offending drugs 
or known metabolic derangements; 
e.g.uremia, ketoacidosis or electrolyte 
imbalance  
9 Haematologic disorder 
a) Haemolytic anaemia – with reticulosis (OR) 
b) Leukopenia – less than 4,000/mm3  total on 2 
or more occasions (OR) 
c) Lymphopenia – less than 1,500/mm3 on 2 or 
more occasions (OR) 
d)  Thrombocytopenia – less than 1,00,000/mm3 
in the absence of offending drugs.  
10 Immunological disorder 
a) Positive LE cell preparation (OR) 
b) Anti – DNA : antibody to native DNA in 
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abnormal titer (OR) 
c) Anti – Sm: Presence of antibody to Sm 
nuclear antigen (OR) 
d) False positive serological tests for syphilis 
known to be positive for atleast 6 months and 
confirmed by Treponema pallidum 
immobilization or fluorescent treponemal 
antibody absorption test.   
11 Antinuclear antibody 
An abnormal titer of antinuclear body by 
immunofluorescence or an equivalent assay at any 
point in time and in the absence of drugs known to 
be associated with “drug induced lupus” syndrome. 
For the purpose of identifying patients in clinical studies, a person shall be said 
to have Systemic Lupus Erythematosus if any 4 or more of the 11 criteria are 
present, serially or simultaneously during any interval of observation. 
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TABLE - 5 
American rheumatology association classification criteria for  
systemic sclerosis - 1980 
 
S.No Criteria Definition 
1 Major criteria 
Proximal scleroderma: thickening, 
tautness of fingers and the skin 
proximal of metacarpophalangeal and 
metatarsophalangeal joints 
2 Minor criteria 
1. Sclerodactyly: thickening,  
    tautness of the skin, limited on  
    fingers 
2. Digital pitting scars of fingertips  
    or loss of substance of distal  
    finger pad 
3. Bibasilar pulmonary fibrosis 
One major or two or more minor criteria have to be fulfilled
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TABLE - 6 
European community criteria for diagnosis of sjogren’s syndrome- 
199646 
S.no Signs & Symptoms Definition 
1 Ocular symptoms 
At least one of the following: 
     a)  Daily dryness of eyes for longer than three months 
     b)  Recurrent sensation of having sand or gravel in the  
          eyes 
     c) Use of artificial tears more than three times Per Day
2 Oral symptoms 
At least one of the following: 
    a)  Daily dryness of mouth, or xerostomia, for longer  
         than three months 
    b)  Recurrent or persistent swelling of salivary glands 
    c)  Frequent use of liquids to assist in swallowing food 
3 Ocular signs 
At least one of the following: 
    a)  Schimmer’s test result of 5 millimeters or less of  
         tear production in five minutes 
    b)  Rose bengal test score of 4 or higher (rose bengal  
         dye stains desiccated  epithelial cells of the cornea  
         and conjunctiva) 
4 Oral signs 
At least one of the following: 
    a)  Abnormal results of salivary scintigraphy 
    b) Abnormal results of sialography 
    c) Unstimulated salivary flow of 1.5 ml or less in 15  
         Minutes
5 Histopathology 
    a)  Inflammatory focus score of one or more per 4  
         square millimeters of glandular tissue (a focus score 
         is defined as a cluster of 50 or more lymphocytes)
6 Autoantibodies 
Presence of one or more of the following: 
   a)  Antinuclear antibodies 
   b)  Rheumatoid factor 
   c)  Anti-Ro/anti–SS-A 
   d)  Anti-La/anti–SS-B
Diagnosis of Sjogren’s syndrome requires four of the above 6 criteria be met, after 
exclusion criteria ruled out. Exclusion criteria are pre-existing lymphoma, 
acquired immunodeficiency syndrome, sarcoidosis or graft-vs.-host disease.  
 
 
 
                                                                      
                                                                        MATERIALS AND METHODS 
24 
 
 
TABLE - 7 
American college of Rheumatology criteria for vasculitis – 199047 
S.No  Criteria 
1 
Giant cell 
(temporal) 
arteritis (GCA) 
1. Age .50 years at onset 
2. New type of headache 
3. Abnormal temporal artery on examination 
4. Elevated erythrocyte sedimentation rate 
5. Temporal artery biopsy shows vasculitis 
Sensitivity 93.5%, specificity 91.2% for 3 
criteria
2 Takayasu arteritis 
1. Age ,40 years at onset 
2. Limb claudication 
3. Decreased brachial artery pulses 
4. Blood pressure .10 mg Hg difference 
between arms 
5. Bruits 
6. Abnormal arteriogram 
Sensitivity 90.5%, specificity 97.8% for 3 
criteria
3 Polyarteritis nodosa (PAN) 
1. Weight loss .4 kg 
2. Livedo reticularis 
3. Testicular pain or tenderness 
4. Myalgias, myopathy, or tenderness 
5. Neuropathy 
6. Hypertension (diastolic .90 mg Hg) 
7. Renal impairment (elevated blood urea  
    nitrogen or creatinine) 
8. Hepatitis B virus 
9. Abnormal arteriography 
10. Biopsy of artery showing neutrophils 
Sensitivity of 82.2%, specificity 86.6% for 3 
criteria
4 
Wegener 
granulomatosis 
(WG) 
1. Nasal or oral inflammation 
2. Chest X-ray showing nodules, infiltrates, or 
cavities 
3. Microscopic hematuria or red cell casts in 
urine 
4. Granulomatous inflammation on biopsy 
Sensitivity of 88.2%, specificity 92% for 2 
criteria
5 
Churg-Strauss 
syndrome 
(CSS) 
1.Asthma 
2. Eosinophilia (.10%) 
3. Neuropathy
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4. Pulmonary infiltrates (non-fixed) 
5. Extravascular eosinophils on biopsy 
Sensitivity 85%, specificity 99.7% for 4 criteria
6 
Henoch-Schonlein 
purpura 
(HSP) 
1. Palpable purpura 
2. Age at onset ,20 years 
3. Bowel angina 
4. Vessel wall neutrophils on biopsy 
Sensitivity 87%, specificity 88% for 2 criteria 
7 
Cutaneous 
leukocytoclastic 
Vasculitis 
1. Age 16 years at onset 
2. Medications that may have precipitated   
    event 
3. Palpable purpura 
4. Cutaneous eruption 
5. Positive biopsy results 
Sensitivity of 71%, specificity 83.9% for 3 
criteria 
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TABLE - 8 
Classification criteria for inflammatory myopathies48,49 
 
 
 
POLYMYOSITIS & DERMATOMYOSITIS – 2001 
 
S.No Criteria 
1 
SKIN LESIONS 
 
a)  Heliotrope:        Red-purple edematous erythema on the upper    
                               palpebra 
b)  Gottron’s sign:  Red-purple keratotic, atrophic erythema or  
                               macules on the extensor surface of finger     
                               joints Erythema on the extensor surface of  
                               extremity joints, slight raised red-purple  
                               erythema over elbows or knees 
2 Proximal muscle weakness                  upper or lower extremity and trunk.
3 Elevated serum creatine kinase or aldolase level
4 Muscle pain on grasping or spontaneous pain
5 
Myogenic changes on electromyography  
                Short-duration, polyphasic motor unit potentials with   
                spontaneous fibrillation potentials 
6 Positive anti-Jo-1 antibody test                  Histidyl-tRNA synthetase 
7 Nondestructive arthritis or arthralgias
8 
Systemic inflammatory signs  
            a) Temperature: more than 37°C [98.6°F] at axilla,   
            b) Elevated serum C-reactive protein level or  
            c) Accelerated erythrocyte sedimentation rate of more   
                than 20 mm per hour by Westergreen)
9 
Pathologic findings compatible with inflammatory myositis 
(inflammatory infiltration of skeletal evidence of active 
regeneration may be seen)
                 
                  Patients presenting with at least one finding from item 1 and four 
findings from items 2 through 9 are said to have dermatomyositis.  
 
                  Patients presenting with at least four findings from items 2 through 
9 are said to have polymyositis 
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INCLUSION BODY MYOSITIS – 1987 
 
S.No Criteria Definition 
1 Pathologic Criteria 
Electron microscopy 
       Microtubular filaments in the inclusions 
Light microscopy 
      1)  Lined vacuoles 
      2)  Intranuclear or intracytoplasmic     
           inclusions, or both
2 Clinical Criteria 
 1) Proximal muscle weakness (insidious onset) 
 2) Distal muscle weakness 
 3) Electromyographic evidence of a generalised 
     myopathy 
 4) Increase in muscle enzyme levels 
 5) Failure of muscle weakness to improve on a  
     high dose regimen of corticosteroids (at least 
    40- 60 mg/day for three to four months) 
Definite inclusion body myositis requires pathological electron microscopy 
criterion I and clinical criterion 1 plus one other clinical criterion. Probable 
inclusion body myositis requires pathological light microscopy criterion I and 
clinical criterion I plus three other clinical criteria. Possible inclusion body 
myositis requires pathological light microscopy criterion 2 plus any three 
clinical criteria. 
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TABLE – 9 
Classification criteria for spondyloarthropathies - 199150 
 
Criterion Definition 
Inflammatory spinal pain with at 
least four of the following five 
components: 
 
 a) At least 3 months in duration 
 b) Onset before 45 years of age 
 c) Insidious (gradual) onset 
 d) Improved by exercise 
 e) Associated with morning  
      spinal stiffness 
History of or current symptoms of spinal 
pain (low, middle, and upper back, or neck 
region) 
Synovitis Past or present asymmetric arthritis, or 
arthritis predominately in the lower limbs 
 
Spondyloarthropathy Presence of inflammatory spinal pain or 
synovitis and one or more of the following 
conditions: 
 
    a) Family history: first- or second-degree  
         relatives with ankylosing spondylitis,   
         psoriasis, acute iritis, reactive   
         arthritis, or  inflammatory bowel  
         Disease 
 
    b) Past or present psoriasis, diagnosed by 
        a physician 
 
     c) Past or present ulcerative colitis or  
         Crohn’s disease, diagnosed by a  
         physician and confirmed by  
         radiography or endoscopy 
 
     d) Past or present pain alternating     
         between the two buttocks 
 
     e) Past or present spontaneous pain or  
         tenderness at examination of the site    
        of the insertion—the Achilles tendon  
        or planter fascia (enthesitis) 
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     f)  Episode of diarrohea occurring within 
         1 month before onset of arthritis 
 
      g) Nongonococcal urethritis or  
          Cervicitis occurring within 1 month  
          before onset of  arthritis 
 
     h) Bilateral grade 2–4 sacroiliitis or  
        unilateral grade 3 or 4 sacroiliitis* 
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TABLE - 10 
Diagnostic criteria for mixed connective tissue disease - 198751 
Common 
Symptoms 
Raynaud’s 
phenomenon, 
Swollen fingers or 
hands 
 
Anti–U1 small 
nuclear RNP 
positive 
  
Mixed findings 
Systemic lupus 
erythematosus–like 
findings 
Polyarthritis lymphadenopathy 
Facial erythema Pericarditis or 
pleuritis Leukopenia (4000/mm3) 
or thrombocytopenia (100000/ 
mm3) 
Systemic sclerosis–
like findings 
Pulmonary fibrosis, restrictive 
changes of the lung (forced vital 
capacity ,80% of predicted), or 
reduced carbon monoxide 
diffusing capacity (70% of 
predicted) Hypomotility or 
dilatation of esophagus 
Polymyositis-like 
findings 
Muscle weakness Elevated serum 
level of muscle enzymes (creatine 
kinase) Myogenic pattern on 
electromyogram 
 
Diagnosis: Mixed connective tissue disease will be diagnosed when all 3 
conditions are fulfilled. 
1. Presence of 1 or both common symptoms 
2. Positive anti–U1 snRNP antibody 
3. Presence of 1 or more findings in at least 2 of the 3 disease categories     
    under “mixed findings” 
 
 
                                                                      
                                                                        MATERIALS AND METHODS 
31 
 
 
TABLE - 11 
Classification criteria for definite Antiphospholipid syndrome - 
199952 
S.No 
 Criteria Definitions 
 
 
1 
 
 
Clinical 
criteria 
Vascular thrombosis 
 
One or more clinical episodes of arterial, venous, or 
small vessel thrombosis, in any tissue or organ. 
Thrombosis must be confirmed by imaging or doppler 
studies or histopathology, with the exception of 
superficial venous thrombosis. For histopathologic 
confirmation, thrombosis should be present without 
significant evidence of inflammation in the vessel 
wall. 
 
Pregnancy morbidity 
 
(a) One or more unexplained deaths of a 
morphologically normal foetus at or beyond the 10th 
week of gestation, with normal foetal morphology 
documented by ultrasound or by direct examination of 
the fetus, or 
 
(b) One or more premature births of a 
morphologically normal neonate at or before the 34th 
week of gestation because of severe preeclampsia or 
eclampsia, or severe placental insufficiency , or 
 
(c) Three or more unexplained consecutive 
spontaneous abortions before the 10th week of 
gestation, with maternal anatomic or hormonal 
abnormalities and paternal and maternal chromosomal 
causes excluded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anticardiolipin antibody of IgG and/or IgM isotype in 
blood, present in medium or high titer, on 2 or more 
occasions, at least 6 weeks apart, measured by for b2-
glycoprotein I–dependent anticardiolipin antibodies 
Lupus anticoagulant present in plasma, on 2 or more 
occasions at least 6 weeks apart, detected according to 
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2 
 
 
Laboratory 
criteria 
the guidelines of the International Society on 
Thrombosis and Hemostasis (Scientific Subcommittee 
on Lupus Anticoagulants/Phospholipid-Dependent 
Antibodies) , in the following steps: 
 
(a) Prolonged phospholipid-dependent coagulation 
demonstrated on a screening test, e.g., activated 
partial thromboplastin time, kaolin clotting time, 
dilute Russell’s viper venom time, dilute prothrombin 
time, Textarin time. 
 
(b) Failure to correct the prolonged coagulation time 
on the screening test by mixing with normal platelet-
poor plasma. 
 
(c) Shortening or correction of the prolonged 
coagulation time on the screening test by the addition 
of excess phospholipid. 
 
(d) Exclusion of other coagulopathies, e.g., factor VIII 
inhibitor or heparin, as appropriate.
 
Definite antiphospholipid antibody syndrome is considered to be present if at 
least 1 of the clinical criteria and 1 of the laboratory criteria are met.  
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TABLE - 12 
Diagnostic criteria for Still’s disease -200053 
S.NO CRITERIA DEFINITION 
1 Major Criteria   ( Two Points) 
Quotidian fever > 39°C
Still's (evanescent) rash 
WBC > 12.0 + ESR > 40 mm/h 
Negative Rheumatoid factor and Anti-
nuclear antibody
Carpal ankylosis
2 Minor Criteria  ( One Point) 
Onset age < 35 years
Arthritis
Prodromal sore throat 
Reticulo endothelial system involvement 
or abnormal Liver Function Tests 
Serositis
Cervical or tarsal ankylosis
 
Probable Still’s Disease: 10 points with 12 weeks' observation 
Definite  Still’s Disease: 10 points with six months' observation 
 
 
 
 
 
 
 
 
 
 
                                                                      
                                                                        MATERIALS AND METHODS 
34 
 
 
TABLE -13 
Scoring criteria for oral hygiene index 
Debris index component 
Score Criteria 
0 No debris or stain present 
1 
 
Soft debris covering not more than 1/3 of the tooth surface. 
and/or presence of extrinsic stains without other debris regardless 
of surface area covered.   
2 
Soft debris covering more than 1/3, but not more than 2/3 of the 
exposed tooth surface.   
3 
 
Soft debris covering more than 2/3 of the exposed tooth surface. 
Calculus index component  
Score Criteria 
0 No calculus present 
1 
 
Supragingival calculus  covering not more than 1/3 of the 
exposed tooth surface.   
 
2 
 
Supragingival calculus covering more than 1/3,but not more than 
2/3 of the exposed tooth surface. and / or the presence of 
individual flecks of subgingival calculus around the cervical 
portion of the tooth or both  
 
3 
 
Supragingival calculus covering more than 2/3 of the exposed 
tooth surface. and/or a continuos heavy band of subgingival 
calculus around the cervical portion of the tooth or both 
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TABLE - 14 
Scoring criteria - CPI and Loss of Attachment index 
CPI index 
Score Criteria 
0 Healthy 
1 Bleeding observed, directly or by using a mouth mirror, after probing.   
2 Calculus detected during probing but all of the black band on the probe visible. 
3 Pocket 4-5 mm (Gingival margin within the black band on the probe) 
4 Pocket 6 mm or more (Black band on the probe not visible) 
X Excluded sextant ( Less than two teeth present) 
9 Not recorded. 
Loss of Attachment index 
Score Criteria 
 
0 
Loss of attachment 0-3 mm (CEJ not visible and CPI score 0-3) 
If the Cemento Enamel Junction (CEJ) is not visible and the CPI 
score is 4, or if the CEJ is visible.
1 Loss of attachment 4-5mm (CEJ within the black band). 
2 Loss of attachment 6 -8 mm (CEJ between the upper limit of the black band and the 8-5 mm ring)
3 Loss of attachment 9- 12mm (CEJ between the 8.5mm and 11.5mm rings) 
4 Loss of attachment 12mm or more (CEJ beyond the 11.5mm rings. 
X Excluded sextant (Less than two teeth present) 
9 Not recorded (CEJ neither visible not detectable). 
 
 
 
 
 
                                                                      
                                                                        MATERIALS AND METHODS 
36 
 
 
 
STATISTICAL ANALYSIS 
Sample size: 
                      Sample size estimation was done initially before the study was 
started. Sample size (n) derived using the following formula: 
 
Where 
α       -  Significance value. (5%) 
1- β  -  Power of the study. (90%) 
p1     -  Anticipated probability of exposure for persons with the disease. (45%) 
p2       -  Anticipated probability of exposure for persons without the disease. 
(25%) 
      P      -  p1 + p2  
                       2 
Analysis: 
¾ Values were tabulated and analyzed using statistical package for social 
sciences (SPSS) version no: 15. 
¾ Categorical variables between case group and control group were 
analyzed using Pearson's chi-square test. 
¾ Pearson's correlation test was done to find correlation among OHI score, 
CPI score and LOA score. 
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S.N 
OP 
No: Age Sex 
 # 
Dia 
$ 
G 
¥ 
P 
* 
OHI 
** 
CPI 
*** 
LOA 
 1 86228 50 F RA P P 2.16 3 1 
2 86125 44 F RA P P 2 3 1 
3 51715 31 F SS P P 2.48 3 1 
4 46221 43 F RA P   3.16 3 1 
5 45533 47 F RA P P 0.98 4 3
6 50821 32 F PM P P 0.66 4 3 
7 49647 45 F RA P P 4.98 3 1 
8 51505 24 M RA P A 1.82 1 0
9 50277 61 M RA P P 5.16 4 2 
10 36843 49 F RA A A 0.32 0 0 
11 46749 44 F RA P P 0.78 4 2
12 50964 50 F VA P P 2.16 4 2 
13 43126 33 F VA P P 1.5 3 1 
14 50798 29 F SLE P P 2.96 4 2
15 51415 42 F SLE P P 4.32 3 1 
16 51286 43 M SS P P 2.32 3 1 
17 48315 33 F RA P P 2.32 3 1
18 49859 55 F RA P A 0.98 1 0 
19 47758 65 F RA P P 4.48 3 1 
20 48399 42 F RA P P 5.16 3 1
21 56857 38 F SSJ P P 2.8 4 2 
22 49998 33 M SPA P P 4.62 3 1 
23 45123 27 M RA P P 1.82 4 3
24 49025 31 F RA P P 2.14 4 2 
25 46377 39 F RA P A 2.14 2 0 
26 49787 40 F RA P P 1.82 4 3
27 40847 35 F RA P P 2.48 3 1 
28 49111 24 F SLE P A 2.98 2 0 
29 50186 39 F RA P P 2.98 4 2
30 47962 47 F RA P A 2.16 2 0 
31 48141 47 F RA P P 2.82 4 2 
32 23242 60 F RA P A 0.82 2 0
33 50613 36 F RA P P 3.16 3 1 
34 180 58 F SSJ A A 0.66 0 0 
35 32815 44 F RA P P 2.66 4 2 
36 51281 44 F RA P P 1.66 2 0 
37 51678 37 F RA P P 4 4 2 
38 41232 28 F SPA P P 2.98 4 2 
39 47312 46 F RA P P 2.16 4 2 
40 28750 54 F RA P A 1.82 2 0 
41 51907 22 F RA P P 1.66 4 2 
42 80268 21 F APS P P 1.82 4 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.N 
OP 
No: Age Sex 
 # 
Dia 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI 
*** 
LOA 
43 45984 36 F RA P P 2.82 4 2 
44 51526 35 F SSJ P P 1.98 4 3 
45 42770 45 F RA P P 2.82 4 2 
46 47703 28 F RA P P 0.74 3 2 
47 40202 65 M SSJ P P 1.16 4 2 
48 41225 15 F SS P P 2.16 4 2 
49 49878 61 F SSJ P P 1.5 4 2 
50 51708 49 M SPA P P 2.48 4 2 
51 44317 38 M SS P P 1.66 4 2 
52 51702 36 F RA P P 1.82 4 2 
53 39468 56 M RA P P 1.98 4 2 
54 41643 55 M RA P P 1.82 4 2 
55 51261 29 F SLE P P 2.32 4 2 
56 52621 36 F SLE P P 2.16 4 2 
57 51752 48 F RA P P 2.32 4 2 
58 51508 19 M SPA P P 2.14 4 2 
59 43621 47 F RA P P 1.5 4 2 
60 50162 30 F RA P P 3 4 2 
61 49288 39 F SS P P 2.82 4 2
62 51438 37 M RA P P 1.82 4 2 
63 51299 55 M RA P P 1.98 4 3 
64 46696 35 F SLE P P 2.5 4 2
65 47670 34 M SPA P P 0.66 4 3 
66 50919 44 M RA P P 2.82 4 2 
67 51749 47 F RA P P 3.32 4 2
68 51602 50 F SS P P 1.32 4 3 
69 41325 25 M SPA P P 2.5 4 2 
70 47043 47 F RA P P 1.98 4 2
71 51878 44 F RA P A 1.66 2 0 
72 46651 42 F DM P A 2.14 2 0 
73 51930 40 F SS P P 1.98 4 3
74 51816 38 F RA P P 0.64 4 2 
75 48176 21 F SS P P 1.48 4 2 
76 47033 37 F RA P P 1.5 4 2
77 47627 47 F RA P P 1.32 4 2 
78 50693 30 F SLE P P 2.32 4 2 
79 50547 25 F SLE P P 1.66 4 2
80 45904 20 F SLE P P 1.82 4 3 
81 47612 42 F SLE P P 1.98 4 2 
82 49598 40 F SLE P P 3.32 4 2
83 51630 27 F SLE P P 2.84 3 1 
84 45302 27 F SLE P P 3.02 4 2 
 
 
 
 
TABLE   -15 
LIST OF PATIENTS IN CASE GROUP 
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S.N 
OP 
No: Age Sex 
 # 
Dia 
$ 
G 
¥ 
P 
* 
OHI 
** 
CPI 
*** 
LOA 
85 49810 37 F SLE P P 2.32 4 2
86 48754 24 F SLE P P 2.32 3 2 
87 57681 19 F SLE P P 3.48 4 2 
88 44263 35 F SLE P P 2.5 4 2
89 50508 19 F SLE P P 2.48 4 3 
90 47497 21 F SLE P P 2.16 4 2 
91 45227 39 F SLE P P 1.98 2 0
92 48163 23 F SLE P P 3.64 4 2 
93 51278 30 F SLE P P 2.5 4 2 
94 50415 53 M SPA P P 3.16 3 1
95 51646 35 F PM P P 1.98 4 2 
96 38780 65 F SS P P 2.98 4 3 
97 45611 35 F RA P A 2.14 2 0
98 49441 19 M SPA P P 2.96 4 2 
99 40764 39 F RA P P 2.98 3 1 
100 51818 56 F RA P P 2.32 4 2
101 49484 47 M RA P P 3 4 2 
102 48634 32 M SS P P 2.82 4 2 
103 51109 32 M SPA P P 2.82 4 3
104 51447 48 F PM P A 1.98 2 0 
105 50877 38 F SPA P P 3.48 4 2 
106 40072 26 F SLE P P 2.66 4 3
107 45795 31 F SLE P P 3.82 4 3 
108 49961 36 F SLE P P 3.49 4 3 
109 50843 26 F SLE P A 4.16 2 0
110 48832 21 F SLE P A 3.5 2 0 
111 49900 22 F SSJ P P 3.33 4 3 
112 47643 21 F SLE P P 3.16 4 3
113 51835 35 F SLE P P 2.46 4 2 
114 51166 34 F SLE P P 3.32 4 2 
115 47245 28 F SLE P A 3.5 2 0
116 47836 25 F SLE P P 3.64 4 2 
117 49170 41 F SLE P A 3.32 2 0 
118 42698 32 F SLE P P 3.5 4 2
119 51779 23 F SLE P P 3.48 3 2 
120 46417 35 F SLE P A 2.32 2 0 
121 51406 23 F SLE P P 3.64 4 2
122 47403 37 F SLE P P 2.66 4 2 
123 46538 37 F SLE P P 2.82 4 2 
124 51809 37 F SLE P P 2.98 4 2
125 46096 35 F SLE P P 2.98 3 1 
126 50607 33 F SS P P 2.49 3 1 
127 51365 37 F SS P P 2.48 4 2
128 43686 29 F VA P A 3.99 2 0 
129 49114 28 F RA P P 3.33 4 2 
130 50933 18 M DM P P 2.82 3 1
 
 
 
 
S.N 
OP 
No: Age Sex 
 # 
Dia 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI 
*** 
LOA 
131 45608 53 F VA P A 2.99 2 0 
132 41626 26 M RA P A 2.99 2 0
133 51910 25 M SPA P P 2.8 4 2 
134 45196 49 M SPA P P 3.3 4 2 
135 51933 19 M SPA P A 3.46 2 0
136 51893 19 F ASD P P 2.99 4 2 
137 46654 40 F RA P P 2.99 4 2 
138 50855 50 F RA P P 3.66 4 2 
139 48942 45 F RA P A 3.16 2 0 
140 51956 42 F RA P P 3.16 3 1 
141 45049 40 F RA P P 3.66 4 2 
142 49206 44 M SS P P 5 4 2 
143 51082 34 M PM P P 4.16 4 2 
144 47597 22 M SPA P A 3.33 2 0 
145 51984 50 F RA P A 3.16 2 0 
146 48235 36 F RA P P 4.83 4 2 
147 48627 34 F SS P P 3.66 4 2 
148 48044 47 F SS P P 4.66 4 2 
149 50008 47 F RA P P 4.66 4 2 
150 50917 46 M RA P A 5 2 0 
151 38330 42 F DM P A 3.49 2 0 
152 51281 44 F RA P A 4.33 2 0 
153 43758 25 M RA P P 4.32 4 2 
154 51715 31 F SS P A 3.32 2 0 
155 48141 44 F RA P P 3.16 4 2 
156 46400 47 M RA P P 4.33 4 2 
157 51597 38 F RA P A 3.16 2 0 
158 48691 39 F SPA P P 2.99 4 2 
159 39390 29 M SPA P P 4.49 4 2 
160 46453 52 M RA P A 3.33 2 0 
161 46019 24 M SPA P P 4.49 3 1 
162 51765 47 F RA P P 4.33 4 2 
163 50223 65 F RA P P 4.92 4 2 
164 51332 22 F RA P P 4 4 2 
165 51937 42 F RA P A 3.32 2 0 
166 49341 34 F SSJ P P 4.32 3 2 
167 50231 47 F SS P A 2.99 2 0 
168 30764 39 F RA P A 3.49 2 0 
169 48293 51 M VA P P 5 4 2 
170 51660 45 M SPA P P 1.66 4 2 
171 50606 44 F SLE P A 2.99 2 0 
172 51304 29 F SLE P A 3.32 2 0 
173 45373 35 F SLE P A 4.16 2 0 
174 51043 35 F SLE P P 3.83 4 2 
175 42083 40 F SLE P A 3.83 2 0 
176 41040 40 F SLE P P 3.99 4 2 
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S.N 
OP 
No: Age Sex 
 # 
Dia 
$ 
G 
¥ 
P 
* 
OHI 
** 
CPI 
*** 
LOA 
177 31476 34 F SLE P P 4.66 4 2 
178 40962 23 F SLE P A 3.49 1 0
179 51242 35 F SLE P P 4.99 4 2 
180 32934 34 F SLE P P 3.66 4 2 
181 51148 40 F SS P A 3.99 2 0
182 51219 21 M SPA P A 4.99 2 0 
183 46661 42 F DM P P 3.5 4 2 
184 51678 26 F ASD P A 3.5 2 0 
185 34878 47 M SPA P P 3.5 4 2 
186 51888 34 M VA P P 4.66 4 2 
187 52007 28 F SLE P P 3.66 4 2 
188 49992 17 F SLE P A 3.99 2 0 
189 44553 45 F SLE P A 4.32 2 0 
190 48745 25 F SLE P A 3.66 2 0 
191 58656 23 F SLE P P 3.83 4 2 
192 41235 24 F SLE P P 1.66 3 1 
193 44473 24 F SLE P P 4.83 4 2 
194 49538 22 F SLE P A 3.49 2 0 
195 50517 25 F SLE P A 3.33 2 0 
196 49142 30 F DM P A 4.16 2 0 
197 49759 41 F SS P A 4 2 0 
198 14105 40 M SPA P P 3.5 4 2 
199 51117 24 F SPA P P 3.49 4 2 
200 37723 34 F SS P A 2.5 4 2 
201 48570 36 M SPA P A 4.83 2 0 
202 51407 34 M SPA P A 4 2 0 
203 50952 28 M VA P P 4.32 4 2 
204 36233 38 F RA P P 4.5 4 2 
205 51847 50 F RA P P 5 3 2 
206 48067 45 F RA P A 4.1 2 0 
207 44304 38 F DM P A 3.49 2 0 
208 52109 35 F RA P P 5 4 2 
209 48136 46 M RA P A 2.32 2 0 
210 50952 32 M SPA P P 4.49 4 2 
211 50273 30 F RA P P 3.83 4 2 
212 52057 38 F RA P P 4.66 4 2 
213 49273 50 M APS P P 4.83 4 2 
214 50195 39 M SPA P P 3.83 4 2 
215 51546 45 M RA P A 4.16 2 0 
 
NOTE: 
#      -   DIAGNOSIS 
$      -   GINGIVITIS 
¥      -   PERIODONTITIS 
*      -   ORAL HYGIENE INDEX SCORE 
**    -   COMMUNITY PERIODONTAL INDEX SCORE 
***  -   LOSS OF ATTACHMENT SCORE 
P      -   PRESENT  
A      -  ABSENT 
 
 
 
 
 
 
 
 
 
 
 
S.N 
OP 
No: Age Sex 
 # 
Dia 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI 
*** 
LOA 
216 52138 26 F RA P P 4.16 4 2 
217 51731 40 F RA P P 5 4 2 
218 35005 31 F RA P P 4.5 4 2 
219 51447 32 F RA P A 4.83 2 0 
220 40515 55 F SS P P 4.33 4 3 
221 50816 33 M SPA P P 4.49 4 2 
222 51430 49 F RA P A 4.16 2 0
223 51155 39 M SPA P P 4.66 4 2 
224 47986 50 M RA P P 4 4 2 
225 50916 48 M SPA P P 3.32 4 2
226 51194 37 F RA P P 5.49 4 2 
227 47965 34 F SS P P 4.33 4 2 
228 51962 32 M SPA P A 4.16 2 0
229 51457 32 F RA P P 4.66 3 1 
230 51591 31 M SPA P A 4.33 2 0 
231 48271 28 F RA P P 4 3 2
232 49264 42 F SS P A 4.16 2 0 
233 49934 39 F RA P P 4.16 4 2 
234 48271 39 M VA P P 3.16 3 0
235 49208 48 F RA P P 4.33 3 2 
236 51130 27 M SPA P A 3.83 2 0 
237 46792 20 F RA P A 3.83 2 0
238 51286 42 M RA P A 4.32 2 0 
239 53516 22 F SPA P P 4.66 3 2 
240 48672 24 F RA P A 4.49 2 0
241 48617 33 F DM P P 3.99 3 2 
242 51740 17 F SS P P 4.16 3 2 
243 49991 43 M SPA P P 4.49 4 2
244 49671 49 F SS P P 4.33 4 2 
245 49938 30 F SS P A 3.99 2 0 
246 45226 32 F SS P P 3.82 4 3
247 51688 37 F MCTD P P 4.49 3 1 
248 50819 30 F RA P P 3.66 3 1 
249 41481 21 F VA P P 3.33 3 1
250 51010 34 F RA P P 3.66 4 3 
251 46169 23 M SPA P P 4 3 1 
252 52130 30 F MCTD P P 4.32 4 2
253 58634 60 M RA P P 4.66 4 2 
 
RA         -  RHEUMATOID ARTHRITIS 
SLE       -  SYSTEMIC LUPUS ERYTHEMATOSUS    
SSJ        -  SJOGRENS SYNDROME 
SS          -  SYSTEMIC SCLEROSIS 
PM         -  POLYMYOSITIS 
DM        -  DERMATOMYOSITIS 
SPA       - SPONDYLOARTHROPATHY 
VA         - VASCULITIS 
MCTD  – MIXED CONNECTIVE TISSUE DISEASE 
ASD      - ADULT ONSET STILLS DISEASE 
APS       - ANTIPHOSPHOLIPID SYNDROME 
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S.N 
OP 
No: Age Sex 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI 
*** 
LOA 
1 45918 39 M P A 1.66 2 0 
2 45924 17 M P A 2.24 2 0 
3 26817 47 M P A 5.16 2 0 
4 48450 32 M P A 3.99 2 0
5 48854 40 F P A 4 2 0 
6 48864 30 M P A 5.83 2 0 
7 48835 40 M P A 4 2 0
8 48399 29 F P A 3.16 1 0 
9 48901 29 M P P 4.16 3 1 
10 48962 22 M A A 1.16 0 0
11 49210 15 F P A 3.33 2 0 
12 50035 46 M P A 3.32 2 0 
13 49486 19 M P A 3.16 2 0
14 41708 37 M P A 3.32 2 0 
15 2155 52 M P P 3.16 3 1 
16 50165 47 m P A 3.16 2 0
17 50041 22 M P A 3.66 2 0 
18 50040 50 M P A 3.16 2 0 
19 57195 16 F P A 3.82 2 0
20 57239 31 F P A 3.16 2 0 
21 50250 22 M P A 4.16 2 0 
22 57235 26 F P A 4.5 2 0
23 57678 19 F P A 3.83 2 0 
24 57699 19 F P A 3.66 2 0 
25 57867 24 M P A 3.5 2 0
26 57721 23 M P A 5.16 2 0 
27 57676 19 F P A 5.33 2 0 
28 57631 40 M P P 4.16 3 1
29 57782 19 M P A 4.33 2 0 
30 57848 32 M P A 5.32 2 0 
31 56261 34 M P A 4 2 0
32 52465 25 M A A 0.33 0 0 
33 58395 41 M P A 4.16 2 0 
34 58347 66 M P A 1.83 2 0
35 47776 25 M P A 3.83 2 0 
36 53178 22 M P A 3.32 2 0 
37 58350 23 F A A 0.5 0 0
38 45176 20 M P A 3.92 2 0 
39 58348 40 F P A 3.83 2 0 
40 58504 25 M A A 0.5 0 0
41 51515 24 M P A 5.66 2 0 
42 58699 30 M P A 4.16 2 0 
 
 
 
 
 
 
 
 
 
 
 
S.N 
OP 
No: Age Sex 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI  
*** 
LOA 
43 59091 36 M P A 4.16 1 0 
44 58685 45 M P A 3.66 1 0 
45 58896 28 M P A 3.49 2 0 
46 54596 37 M A A 0.5 0 0 
47 53367 52 M P P 4.99 3 1 
48 59960 58 M P A 4.03 1 0 
49 59908 19 F A A 1.16 0 0 
50 60000 47 F A P 4.19 4 2 
51 59910 17 F A A 0.82 0 0 
52 53046 23 F P P 5 3 1 
53 60077 61 F P A 3.99 2 0 
54 60275 37 F P A 3.49 1 0 
55 60277 39 F A A 0.5 1 0 
56 60374 42 F P P 4.66 3 1 
57 60313 34 M P A 4.86 1 0 
58 59860 49 M P P 5.16 3 1 
59 55667 56 F P A 5.16 1 0 
60 60683 23 F A A 0.83 0 0 
61 60698 25 F A A 0.5 0 0 
62 60687 21 F P A 3.16 1 0 
63 60700 20 F A A 0.5 0 0 
64 60976 28 F P A 3.49 1 0 
65 61068 29 M P A 4.5 1 0 
66 61082 65 F P P 4.66 3 1 
67 61328 21 F P A 4 1 0 
68 61351 16 F A A 0.5 0 0 
69 45168 46 F P A 4.16 2 0 
70 61544 65 F P P 4.82 3 1 
71 62229 22 F P A 3.99 1 0 
72 62296 50 M P P 4.32 3 1 
73 62650 23 F P A 3.83 1 0 
74 64756 41 F P A 3.32 1 0 
75 66684 36 F P A 3.16 1 0 
76 66701 26 F P A 3.83 1 0 
77 67246 38 M P A 3.99 1 0 
78 66446 54 F P A 4.66 3 1 
79 67269 52 M P A 3.83 1 0 
80 67257 43 M P A 3.49 3 1 
81 62288 40 F P P 3.82 3 1 
82 67736 50 M P P 3.5 3 1 
83 67502 28 M P P 5.66 4 2 
84 67885 27 F P A 3.49 2 0 
 
 
 
 
                                         TABLE   -16 
              LIST OF PATIENTS IN CONTROL GROUP 
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S.N 
OP 
No: Age Sex 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI 
*** 
LOA 
85 67706 19 F A A 0.5 0 0 
86 67744 46 F A A 0.5 0 0
87 67764 32 M P A 4.83 1 0 
88 67802 23 F P A 3.83 1 0 
89 67843 68 F P P 3.66 3 1
90 68031 37 F P A 3.33 1 0 
91 68151 40 F P A 3 1 0 
92 68083 18 F P A 2.83 1 0 
93 63404 42 F P A 3.16 1 0 
94 68480 27 M P A 4.92 1 0
95 68479 26 M P A 5.33 1 0 
96 68437 44 F P P 5.8 4 2 
97 69115 29 M P P 4.99 3 1
98 69134 17 F P A 3.16 1 0 
99 70499 28 f A A 0.46 0 0 
100 70809 23 f P A 3.49 1 0
101 67242 27 F P A 2.66 1 0 
102 77697 36 F P A 4.53 1 0 
103 77701 18 F P A 4.33 1 0
104 77691 42 M P A 4.53 2 0 
105 77777 24 M P A 2.99 1 0 
106 77770 55 M P P 5 3 1
107 78025 46 M P P 5.16 3 1 
108 73604 21 F P A 3.16 1 0 
109 78119 17 F P A 2.83 1 0
110 78098 21 F P A 2.33 1 0 
111 78008 16 F P A 2.16 1 0 
112 78183 48 F P P 5.66 3 1
113 78104 27 F A A 0.33 0 0 
114 78343 54 F P A 2.6 1 0 
115 74403 43 F P A 2.5 1 0
116 78356 35 F P A 3.16 1 0 
117 74965 42 M P A 4.66 1 0 
118 78477 30 F P A 2.49 1 0
119 78474 42 M P P 4.99 3 1 
120 78445 31 M P A 4 2 0 
121 78761 24 F P A 3 1 0
122 79504 20 F P A 2.33 1 0 
123 70874 20 F P A 2.83 1 0 
124 79502 26 F P A 3 1 0
125 79232 18 F P A 4.33 1 0 
126 79662 55 F P A 1.49 1 0 
127 75520 59 M P A 1.83 1 0
128 79737 19 F P A 2.83 1 0 
129 79740 25 F P A 3 1 0 
130 79744 48 F P A 4.83 1 0
131 79828 26 F P A 3.16 1 0 
 
 
 
 
 
 
S.N 
OP 
No: Age Sex 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI  
*** 
LOA 
132 79822 26 F P A 4.33 1 0 
133 79814 20 F P A 2.5 1 0
134 75419 32 F P P 6.16 3 1 
135 79781 26 F P A 2.66 1 0 
136 79896 25 F P A 2.66 1 0 
137 79654 33 F P A 2.83 2 0 
138 80213 27 F P A 2.83 2 0 
139 80337 27 F P A 2.66 2 0 
140 73082 40 F P A 3.82 1 0 
141 80224 40 F P P 2.66 3 1
142 47104 36 F P A 2.66 1 0 
143 80218 30 F P P 5 4 2 
144 80163 26 F P A 2.33 1 0
145 80553 41 F P A 2.66 1 0 
146 80561 30 F P A 2.66 1 0 
147 80506 25 F P A 2.33 1 0
148 80598 26 F P A 4.99 1 0 
149 80666 32 F P A 5.26 1 0 
150 80667 33 F P A 2.66 1 0
151 80691 25 F P A 3.99 1 0 
152 80685 28 F P A 2.5 1 0 
153 80785 26 F P A 2.5 2 1
154 81066 36 F P A 2.33 1 0 
155 81040 25 F P A 2.66 1 0 
156 81062 30 F P P 2.83 3 1
157 81075 25 F P A 4.66 1 0 
158 81259 34 F P A 3.19 1 0 
159 81604 26 F P A 2.99 1 0
160 81732 40 F P P 3.83 3 1 
161 80887 38 F P P 5.66 3 1 
162 82307 35 F A A 0.66 0 0
163 80993 35 F P A 2.66 1 0 
164 74917 42 F P A 2.33 1 0 
165 82281 28 F P A 2.5 1 0
166 82447 47 F P A 3.99 1 0 
167 82437 32 F P A 2.5 1 0 
168 82438 31 F P A 2.5 1 0
169 82432 25 F P A 2.66 1 0 
170 80272 45 F P P 5.16 3 2 
171 82458 32 F P A 3.16 1 0
172 82484 32 F P A 3.32 1 0 
173 76529 50 F A A 0.5 0 0 
174 82368 32 F P A 4.32 1 0
175 82879 25 F P A 2.33 1 0 
176 82964 39 F A A 0.66 0 0 
177 82935 45 F A A 0.49 0 0
178 76816 43 F A A 0.83 0 0 
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S.N 
OP 
No: Age Sex 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI 
*** 
LOA 
179 82970 40 F A A 0.83 0 0 
180 77091 25 F P A 2.82 1 0
181 83015 48 F P A 5.16 1 0 
182 83012 27 F P A 2.5 1 0 
183 83000 47 F P A 4.83 1 0 
184 83020 35 F P A 2.33 1 0 
185 83051 25 F P A 2.83 1 0 
186 83072 42 F P A 2.5 1 0 
187 83159 33 F P A 4.49 1 0 
188 84207 35 F A A 0.83 0 0
189 80262 37 F A A 0.66 0 0 
190 84228 52 F A A 0.66 0 0 
191 84241 33 F P A 2.66 1 0
192 82081 54 M P P 2.66 3 1 
193 82680 42 F A A 0.49 0 0 
194 86392 41 F A A 0.33 0 0
195 68903 39 F P P 5.03 4 2 
196 82623 48 F A A 0.16 0 0 
197 86752 28 F P P 2.5 3 1
198 86800 25 F P A 2.03 1 0 
199 86701 47 F A A 0.33 0 0 
200 86785 38 F A A 0.66 0 0
201 86697 39 F A A 0.66 0 0 
202 86696 49 F P A 2.32 1 0 
203 86884 40 F P A 2.19 1 0
204 86894 42 F P A 3.16 1 0 
205 83591 50 F P A 5 3 1 
206 87369 36 F A A 0.49 0 0
207 87386 56 F A A 0.32 0 0 
208 41418 44 F P A 3.33 0 0 
209 84791 36 F P A 2.99 1 0
210 60085 44 F P A 2.66 1 0 
211 12379 41 F P A 5.33 1 0 
212 87735 37 F P A 5.66 1 0
213 86636 39 F P A 5.16 1 0 
214 82598 35 F P A 4.69 1 0 
215 87790 53 F P P 3.16 3 1
216 86766 50 F P P 2.36 4 2 
217 87958 35 F P A 2.33 1 0 
218 88223 31 F P A 4.66 1 0
219 88530 43 F P A 2.33 3 1 
220 88580 40 F P A 2.49 1 0 
221 87105 40 F P A 2.82 1 0
222 88660 50 F P P 3.16 3 1 
223 88551 49 F P A 2.82 1 0 
224 88738 35 F P A 2.66 1 0
 
 
 
 
 
 
 
S.N 
OP 
No: Age Sex 
$ 
G 
¥ 
P 
* 
OHI  
** 
CPI  
*** 
LOA 
225 88855 35 F P A 2.33 1 0 
226 88852 35 F A A 0.66 0 0
227 88851 28 F A A 0.49 0 0 
228 88959 36 F P A 2.19 1 0 
229 85994 49 F P P 2.83 3 1
230 86222 36 F P A 2.66 1 0 
231 89079 35 F P A 3.33 1 0 
232 89077 45 F P P 4.66 3 1
233 89094 47 F P A 3.66 1 0 
234 89142 36 F P A 2.82 1 0 
235 89129 38 F P A 3.66 1 0
236 89160 38 F P A 2.66 1 0 
237 89239 38 F P A 4.99 1 0 
238 89829 35 F P A 2.33 1 0
239 89835 38 F P P 5.49 4 2 
240 89956 38 F P A 5.49 1 0 
241 89924 39 F P A 2.83 1 0
242 90091 50 F P A 3.5 1 0 
243 90064 46 F A A 2.49 0 0 
244 90115 38 F P P 4.32 3 1
245 86729 36 F P A 3.32 1 0 
246 90325 50 F P A 1.83 1 0 
247 91045 37 F P A 5.99 1 0
248 86232 45 F P A 1.82 1 0 
249 86225 50 F P P 2.16 3 1 
250 86334 43 F P A 3.16 1 0
251 86745 56 F P A 0.83 2 0 
252 86453 63 F P A 0.83 1 0 
253 87456 26 M P A 2.16 2 0
254 88789 27 M P A 2.33 2 0 
255 88798 37 M P A 3.16 2 0 
256 88978 48 M A A 0.49 2 0
257 88988 52 M P A 2.33 1 0 
258 89123 55 M P A 1.83 1 0 
259 89465 61 M P A 1.82 1 0
260 88789 38 M P A 3 1 0 
261 87890 36 M P A 3.33 1 0 
262 88788 50 M P A 2.16 2 0
 
NOTE: 
 
$     -   GINGIVITIS 
¥      -    PERIODONTITIS 
*      -    ORAL HYGIENE INDEX SCORE 
**    -    COMMUNITY PERIODONTAL INDEX SCORE 
***  -    LOSS OF ATTACHMENT SCORE 
P      -   PRESENT  
A      -  ABSENT 
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RESULTS 
                     The distribution of patients in case group and control group with 
respect to age, sex and OHI was showed in Table – 17. None of the patients 
have the OHI score 8.1-12. Female patients were more than male patients in 
both groups. (Case group: Male - 61, Female – 192; Control group: Male - 69, 
Female- 193). 
                     The distribution of patients among case group within various 
systemic autoimmune diseases was showed in Table – 18. (Rheumatoid 
arthritis -98, Systemic lupus erythematosus – 60,  Spondyloarthropathy – 35, 
Systemic sclerosis - 27,  Inflammatory myopathies - 11, Sjogrens syndrome, 
vasculitis, Mixed connective tissue disease, Antiphospholipid syndrome and 
adult onset stills disease – 23) 
 
                    Prevalence of periodontal disease was more in case group 
(Gingivitis 99.2% & Periodontitis 73.9%) than control group (Gingivitis 
85.5% & Periodontitis 14.9%) with P< 0.05. (Table – 19, Figure – 1) 
  
                    Prevalence of periodontal disease among various systemic 
autoimmune diseases in case group (Table – 20, Figure – 2) showed Gingivitis 
100% in all systemic autoimmune diseases except in  Rheumatoid arthritis – 
98.9% &  Sjogrens  syndrome – 85.7%.  Periodontitis  >  70%  in  all  systemic  
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autoimmune diseases except in Inflammatory myopathies – 63.6% and Adult 
onset stills diseases – 50%.  
 
                       Prevalence of periodontal disease in male (Gingivitis 100% 
Periodontitis 75.4%) and female (Gingivitis 99% Periodontitis 73.4%) 
patients of case group was more than male (Gingivitis 92.8% Periodontitis 
18.8%) and female (Gingivitis 82.9% Periodontitis 13.5%) patients of control 
group with significant p-value. (Table -21, Figure – 3). 
 
                        In all OHI groups prevalence of periodontitis was more in case 
group than control group with significant p-value (P<0.05). In OHI group 4.1 -
8.0 there was no statistical difference in prevalence of gingivitis between case 
and control group. (Table -22, Figure -4).   
 
                        Prevalence of gingivitis was more in case group than control 
group in all age groups except in 55-64 years and 65-74 years with statistical 
difference (P<0.05). (Table – 23, Figure -5). 
 
                       Prevalence of periodontitis was more in case group than control 
group in all age groups except in 65-74years with statistical difference 
(P<0.05). (Table – 24, Figure -6). 
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                    Prevalence of periodontitis was more in male and female patients 
of case group than control group in all OHI groups with statistical significant 
value (P<0.05). In the OHI group 4.1-8, prevalence of gingivitis among groups 
showed no statistical difference. (Table – 25, Figure -7 & 8). 
 
                      Patients with OHI score 0-4, showed more prevalence of 
periodontitis in case group than control group in all age groups. except in age 
65-74 years, with P<0.05. It not showed much difference for prevalence of 
gingivitis among groups in age groups 55-64 years, and 65-74 years. (Table–
26, Figure -9 & 10). 
 
                     Patients with OHI score 4.1-8, showed more prevalence of 
periodontitis in case group than control group in age groups 15-24 years, 25-34 
years and 35-44 years with P<0.05. It showed no statistical difference in 
prevalence of gingivitis between groups. (Table – 27, Figure -11 & 12). 
 
                    There was no statistical difference with all OHI groups in 
prevalence of periodontal disease among various systemic autoimmune 
diseases in case group with p-value > 0.05. (Table – 28 & 29). 
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                      Higher scores of CPI and LOA were more prevalent in patients of 
case group than control group. Score 3 of LOA was present only in case group 
not in control group. (Table – 30, Figure -13).   
 
                      Higher scores of CPI and LOA were more prevalent in all OHI 
groups of case group, irrespective of OHI scores. In contrast higher scores were 
more present only in higher OHI scores among control group and it reduced 
when OHI scores reduced. (Table – 31 & 32,  Figure -14 & 15). 
  
                      In case group there was no correlation among OHI scores, CPI 
scores and LOA scores with p- value >0.01. (Table – 33). 
 
                      In control group there showed correlation among OHI scores, CPI 
scores and LOA scores with significant p- value < 0.01. (Table – 34). 
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TABLE – 17 
Distribution of patients among case group and control group 
 
 
Groups Subgroups Case Group Control Group Count % Count % 
Age 
Group 
15 – 24 39 15.4 44 16.8 
25 – 34 69 27.3 73 27.9 
35 – 44 84 33.2 84 32.1 
45 – 54 46 18.2 46 17.6 
55 – 64 11 4.3 11 4.2 
65 – 74 4 1.6 4 1.5 
Total 253 100 262 100 
Sex 
Group 
Male 61 24.1 69 26.3 
Female 192 75.9 193 73.7 
Total 253 100 262 100 
OHI 
Group 
0 – 4.0 188 74.3 193 73.7 
4.1 – 8.0 65 25.7 69 26.3 
8.1 – 12.0 0 0 0 0 
Total 253 100 262 100 
 
 
TABLE – 18 
 
Distribution of patients with various systemic autoimmune diseases among 
case group  
 
Systemic autoimmune diseases Case Group 
Count % 
Rheumatoid arthritis 98 38.7 
Systemic lupus erythematosus 60 23.7 
Systemic sclerosis 27 10.7 
Sjogrens syndrome 7 2.8 
Vasculitis 9 3.6 
Inflammatory myopathies 11 4.3 
Spondyloarthropathy 35 13.8 
Mixed connective tissue disease 2 0.8 
Antiphospholipid syndrome 2 0.8 
Adult onset still’s disease 2 0.8 
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TABLE – 19 
 
Comparison of periodontal disease prevalence among case group and  
control group 
 
Periodontal 
disease  
Case Group Control Group Chi-
value P-value Count % Count % 
Gingivitis 
Present 251 99.2 224 85.5 
33.788 0.000** Absent 2 0.8 38 14.5 
Total 253 100 262 100 
Periodontitis 
Present 187 73.9 39 14.9 
182.109 0.000** Absent 66 26.1 223 85.1 
Total 253 100 262 100 
 
      Note :   ** - Highly significant 
 
 
 
 
FIGURE – 1 
 
Comparison of periodontal disease prevalence among case group and  
control group 
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TABLE – 20 
Prevalence of periodontal disease among various systemic autoimmune 
diseases within case group 
 
 
S.no 
Systemic 
autoimmune 
diseases 
Total 
cases 
Prevalence of periodontal diseases 
Gingivitis Periodontitis 
Counts % Counts % 
1 Rheumatoid arthritis 98 97 98.9 73 74.5 
2 Systemic lupus 
erythematosus 60 60 100 44 73.3 
3 Systemic sclerosis 27 27 100 20 74.1 
4 Sjogrens syndrome 7 6 85.7 6 85.7 
5 Vasculitis 9 9 100 7 77.8 
6 Inflammatory 
myopathies 11 11 100 7 63.6 
7 Spondyloarthropathy 35 35 100 27 77.1 
8 Mixed connective 
tissue disease 2 2 100 2 100 
9 Antiphospholipid 
syndrome 2 2 100 2 100 
10 Adult onset still’s 
disease 2 2 100 1 50 
 
 
FIGURE -2 
Prevalence of periodontal disease among various systemic autoimmune 
diseases within case group          
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8. Mixed connective  
    tissue disease 
9. Antiphospholipid  
    syndrome 
10. Adult onset still’s  
      disease 
 
                                                                                                                              
                                                                                                                       RESULTS 
50 
 
 
 
 
TABLE – 21 
 
Comparison of periodontal disease prevalence among case group and 
control group within sex subgroup 
 
Periodontal 
disease 
Sex 
Group  
Case Group Control Group Chi – 
Value 
P – 
Value Count % Count % 
Gingivitis 
Male Present 61 100 64 92.8 4.597 0.032* Total 61 100 69 100 
Female Present 190 99 160 82.9 30.026 0.000** Total 192 100 193 100 
Periodontitis 
Male Present 46 75.4 13 18.8 41.800 0.000** Total 61 100 69 100 
Female Present 141 73.4 26 13.5 140.915 0.000** Total 192 100 193 100 
     
 Note :   * * - Highly significant;     * - Significant 
 
 
 
 
 
FIGURE – 3 
 
Comparison of periodontal disease prevalence among case group and 
control group within sex subgroup 
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TABLE – 22 
 
Comparison of periodontal disease prevalence among case group and 
control group within OHI subgroups 
 
Periodontal 
disease 
OHI 
group  
Case Group Control Group Chi - 
Value 
P – 
Value Count % Count % 
Gingivitis 
0 – 4.0 Present 186 98.9 156 80.8 33.982 0.000** Total 188 100 193 100 
4.1 – 8 Present 65 100 68 98.6 0.949 0.330$ Total 65 100 69 100 
8.1 - 12 Total 0 0 0 0 - - 
Periodontitis 
0 – 4.0 Present 139 73.9 14 7.3 176.212 0.000** Total 188 100 193 100 
4.1 – 8 Present 48 73.8 25 36.2 19.095 0.000** Total 65 100 69 100 
8.1 - 12 Total 0 0 0 0 - - 
 
   Note :   * * - Highly significant;    $ - Not significant 
 
 
 
FIGURE – 4 
 
Comparison of periodontal disease prevalence among case group and 
control group within OHI subgroups 
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TABLE – 23 
 
Comparison of gingivitis prevalence among case group and control group 
within age group 
 
Age 
Group  
Case Group Control Group Chi – 
Value 
P - 
Value Count % Count % 
15 – 24 Present 39 100 36 81.8 7.847 0.005** Total 39 100 44 100 
25 – 34 Present 69 100 67 91.8 5.921 0.015* Total 69 100 73 100 
35 – 44 Present 84 100 70 83.3 15.273 0.000** Total 84 100 84 100 
45 – 54 Present 45 97.8 37 80.4 7.180 0.007** Total 46 100 46 100 
55 – 64 Present 10 90.9 10 90.9 0.000 1.000$ Total 11 100 11 100 
65 - 74 Present 4 100 4 100 - - Total 4 100 4 100 
 
           Note :   * * - Highly significant;     * - Significant;  $ - Not significant 
 
 
FIGURE – 5 
 
Comparison of gingivitis prevalence among case group and control group 
within age group 
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TABLE – 24 
 
Comparison of periodontitis prevalence among case group and control 
group within age group 
 
Age 
Group  
Case Group Control Group Chi – 
Value 
P – 
Value Count % Count % 
15 – 24 Present 28 71.8 1 2.3 43.959 0.000** Total 39 100 44 100 
25 – 34 Present 52 75.4 7 9.6 63.187 0.000** Total 69 100 73 100 
35 – 44 Present 64 76.2 11 13.1 67.658 0.000** Total 84 100 84 100 
45 – 54 Present 31 67.4 16 34.8 9.787 0.002** Total 46 100 46 100 
55 – 64 Present 8 72.7 1 9.1 9.214 0.002** Total 11 100 11 100 
65 – 74 Present 4 100 3 75 1.143 0.285$ Total 4 100 4 100 
            
                 Note :   * * - Highly significant;  $ - Not significant 
 
 
 
FIGURE – 6 
 
Comparison of periodontitis prevalence among case group and control 
group within age group 
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TABLE – 25 
 
Comparison of periodontal disease in patients among case group and control group  
within OHI and sex group 
 
Periodontal 
disease 
OHI 
Group 
Sex 
Group
Total Count Prevalence of periodontal disease 
Chi - 
Value 
P – 
Value Cases Controls 
Case Group Control Group 
Count % Count % 
Gingivtis 
0 – 4.0 
Male 37 41 37 100 36 87.8 4.821 0.028* 
Female 151 152 149 98.7 120 78.9 29.594 0.000** 
4.1 – 8.0 
Male 24 28 24 100 28 100 - - 
Female 41 41 41 100 40 97.6 1.012 0.314$  
Periodontitis 
0 – 4.0 
Male 37 41 29 78.4 3 7.3 40.592 0.000** 
Female 151 152 110 72.8 11 7.2 135.943 0.000** 
4.1 – 8.0 
Male 24 28 17 70.8 10 35.7 6.385 0.012* 
Female 41 41 31 75.6 15 36.6 12.676 0.000** 
 
                Note :   * * - Highly significant;     * - Significant;  $ - Not significant 
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FIGURE – 7 
 
Comparison of gingivitis prevalence among case group and control group  
within OHI and sex group 
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FIGURE – 8 
 
Comparison of periodontitis prevalence among case group and  
control group within OHI and sex group 
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TABLE – 26 
 
Comparison of periodontal disease in patients among case group and control group  
within OHI group (OHI Score 0 - 4.0)  and age group 
 
Periodontal 
disease 
Age 
Group 
Total Count Prevalence of periodontal disease 
Chi - 
Value 
P – 
Value Cases Controls 
Case Group Control Group 
Count % Count % 
Gingivitis 
15 – 24 33 36 33 100 28 77.8 8.295 0.004** 
25 – 34 49 52 49 100 46 88.5 6.011 0.014* 
35 – 44 65 64 65 100 50 78.1 15.950 0.000** 
45 – 54 31 31 30 96.8 23 74.2 6.369 0.012* 
55 - 64 8 8 7 87.5 7 87.5 0.000 1.000$ 
65 - 74 2 2 2 100 1 100 - - 
Periodontitis 
15 – 24 33 36 24 72.7 0 0 40.145 0.000** 
25 – 34 49 52 37 75.5 2 3.8 54.660 0.000** 
35 – 44 65 64 50 76.9 3 4.7 69.518 0.000** 
45 – 54 31 31 21 67.7 8 25.8 10.949 0.001** 
55 - 64 8 8 5 62.5 0 0 7.273 0.007** 
65 - 74 2 2 2 100 1 50 1.333 0.248$ 
 
                     Note :   * * - Highly significant;    * - Significant;    $ - Not significan 
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FIGURE – 9 
 
Comparison of gingivitis prevalence among case group and control group 
within OHI group (OHI Score 0 - 4.0) and age group 
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FIGURE – 10 
 
Comparison of periodontitis prevalence among case group and control 
within OHI group (OHI Score 0 - 4.0) and age group 
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TABLE – 27 
 
Comparison of periodontal disease in patients among case group and control group  
within OHI group (OHI  Score 4.1 – 8.0)  and age group 
 
Periodontal 
disease 
Age 
Group 
Total Count Prevalence of periodontal disease 
Chi - 
Value 
P – 
Value Cases Controls 
Case Group Control Group 
Count % Count % 
Gingivitis 
15 - 24 6 8 6 100 8 100 - - 
25 – 34 20 21 20 100 21 100 - - 
35 – 44 19 20 19 100 20 100 - - 
45 – 54 15 15 15 100 14 93.3 1.034 0.309$ 
55 - 64 3 3 3 100 3 100 - - 
65 – 74 2 2 2 100 2 100 - - 
Periodontitis 
15 – 24 6 8 4 66.7 1 12.5 4.381 0.036* 
25 – 34 20 21 15 75 5 23.8 10.744 0.001** 
35 – 44 19 20 14 73.7 8 40 4.496 0.034* 
45 – 54 15 15 10 66.7 8 53.3 0.556 0.456$ 
55 – 64 3 3 3 100 1 33.3 3.000 0.083$ 
65 - 74 2 2 2 100 2 100 - - 
 
                       Note :   * * - Highly significant;     * - Significant;  $ - Not significant 
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FIGURE – 11 
 
Comparison of gingivitis prevalence among case group and control group 
within OHI group (OHI  Score 4.1 – 8.0) and age group 
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FIGURE – 12 
 
Comparison of periodontitis prevalence among case group and control 
within OHI group (OHI  Score 4.1 – 8.0) and age group 
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TABLE – 28 
 
Comparison of gingivitis prevalence among various autoimmune diseases in case group within OHI group 
 
Systemic 
autoimmune 
diseases 
Total count in 
OHI group 
Prevalence of gingivitis in OHI 
group 
Chi - 
Value P – Value OHI Score
0-4 
OHI 
Score 
4.1-8 
OHI Score 0-4 OHI Score 4.1-8 
Count % Count % 
Rheumatoid arthritis 68 30 67 98.5 30 100 0.446 0.504$ 
Systemic lupus 
erythematosus 53 7 1 1.5 7 100 - - 
Systemic sclerosis 20 7 20 100 7 100 - - 
Sjogrens syndrome 6 1 5 83.3 1 100 0.194 0.659$ 
Vasculitis 6 3 6 100 3 100 - - 
Inflammatory 
myopathies 9 2 9 100 2 100 - - 
Spondyloarthropathy 23 12 23 100 12 100 - - 
Mixed connective 
tissue disease 0 2 - - 2 100 - - 
Antiphospholipid 
syndrome 1 1 1 100 1 100 - - 
Adult onset still’s 
disease 2 0 2 100 - - - - 
 
                                    Note :   $ - Not significant 
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TABLE – 29 
 
Comparison of periodontitis prevalence among various autoimmune diseases in case group  
within OHI group 
 
Systemic 
autoimmune 
diseases 
Total count in OHI 
group 
Prevalence of periodontitis in OHI 
group 
Chi – 
Value 
P – 
Value OHI 
score 0-4 
OHI 
score 
4.1-8 
OHI score 0-4 OHI score 4.1-8 
Count % Count % 
Rheumatoid arthritis 68 30 50 73.5 22 73.3 0.000 0.984$ 
Systemic lupus 
erythematosus 53 7 40 75.5 4 57.1 1.062 0.303
$ 
Systemic sclerosis 20 7 14 70 6 85.7 0.667 0.414$ 
Sjogrens syndrome 6 1 5 83.3 1 100 0.194 0.659$ 
Vasculitis 6 3 4 66.7 3 100 1.286 0.257$ 
Inflammatory 
mkyopathies 9 2 5 55.6 1 50 0.020 0.887
$ 
Spondyloarthropathy 23 12 19 82.6 8 66.7 1.137 0.286$ 
Mixed connective 
tissue disease 0 2 - - 2 100 - - 
Antiphospholipid 
syndrome 1 1 1 100 1 100 - - 
Adult onset still’s 
disease 2 - 1 50 - - - - 
 
                                    Note :   $ - Not significant 
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TABLE – 30 
 
Comparison of CPI score and LOA score among case group and  
control group 
 
 Score Case Group Control Group Chi - Value 
P – 
Value Count % Count % 
CPI 
Score 
0 2 0.8 36 13.7 30.421 0.000** 
1 3 1.2 133 50.8 124.265 0.000** 
2 62 24.5 50 19.1 1.286 0.257$ 
3 39 15.4 36 13.7 0.120 0.729$ 
4 147 58.1 7 2.7 127.273 0.000** 
Total 253 100 262 100   
LOA 
Score 
0 68 26.9 218 83.2 78.671 0.000** 
1 28 11.1 36 13.7 1.000 0.317$ 
2 135 53.4 8 3.1 112.790 0.000** 
3 22 8.7 0 0 - - 
4 0 0 0 0 - - 
Total 253 100 262 100   
 
      Note :   * * - Highly significant;   $ - Not significant 
 
 
 
FIGURE  – 13 
 
Comparison of CPI score and LOA score among case group and  
control group 
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TABLE -31 
 
Comparison of CPI score among case group and control group  
within OHI group 
 
OHI 
Score 
CPI 
Score 
Case Group Control Group Chi - 
Value 
P – 
Value Count % Count % 
OHI 
score 0-
4 
0 2 4.5 34 73.9 
66.433 0.000** 
1 2 4.5 8 17.4 
2 6 13.6 4 8.7 
3 4 9.1 0 0 
4 30 68.2 0 0 
Total 44 100 46 100 
OHI 
score 
4.1-8.0 
0 0 0 0 0 
51.855 0.000** 
1 0 0 29 42 
2 17 26.2 13 18.8 
3 13 20 21 30.4 
4 35 53.8 6 8.7 
Total 65 100 69 100 
     
 Note :   * * - Highly significant;  
 
 
 
FIGURE -14 
 
Comparison of CPI score among case group and control group  
within OHI group 
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TABLE -32 
 
Comparison of LOA score among case group and control group  
within OHI group 
 
OHI 
Score 
LOA 
Score 
Case Group Control Group Chi - 
Value 
P – 
Value Count % Count % 
OHI 
score 0-
4 
0 51 27.1 176 91.2 
183.284 0.000** 
1 20 10.6 16 8.3 
2 96 51.1 1 0.5 
3 21 11.2 0 0 
4 0 0 0 0 
Total 188 100 193 100 
OHI 
score 
4.1-8.0 
0 17 26.2 42 60.9 
38.912 0.000** 
1 8 12.3 20 29 
2 39 60 7 10.1 
3 1 1.5 0 0 
4 0 0 0 0 
Total 65 100 69 100 
       
Note :   * * - Highly significant;     
 
 
 
 
FIGURE -15 
Comparison of LOA score among case group and control group  
within OHI group 
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TABLE – 33 
 
Correlation among OHI score, CPI score and LOA score among case group 
 
  OHI score CPI score LOA score 
OHI score 
Correlation value (r) 1 -0.005 -0.100 
P-Value - 0.936$ 0.113$ 
CPI score 
Correlation value (r) -0.005 1 0.918 
P-Value 0.936$ - 0.000** 
LOA score 
Correlation value (r) -0.100 0.918 1 
P-Value 0.113$ 0.000** - 
 
       Note :   * * - Highly significant;   $ - Not significant 
 
 
 
TABLE – 34 
 
Correlation among OHI score, CPI score and LOA score among control 
group 
 
  OHI score CPI score LOA score 
OHI score 
Correlation value (r) 1 0.589 0.348 
P-Value - 0.000** 0.000** 
CPI score 
Correlation value (r) 0.589 1 0.799 
P-Value 0.000** - 0.000** 
LOA score 
Correlation value (r) 0.348 0.799 1 
P-Value 0.000** 0.000** - 
 
          Note :   * * - Highly significant;  
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DISCUSSION 
 
                      Immune mechanism and their effects are similar for both 
systemic autoimmune diseases and periodontal diseases. Increased  production 
of cytokines and abnormal immune mediated inflammatory response12 are the 
pathogenic mechanism in both the condition.7,11 They are mediated mainly by 
inflammatory cytokines such as IL-1, TNF and PG E2. 13   
 
                     Studies have been done to find the association between 
periodontal diseases and various systemic autoimmune diseases independently. 
There were no studies to evaluate the periodontal condition of  systemic 
autoimmune disease as a single group. Hence this study has been done to 
evaluate the periodontal condition of systemic autoimmune diseases.  
 
Rheumatoid arthritis 
                     Studies conducted by Eduardo de Paula Ishi et al., in 200813(39 
Patients), Biyikoglu B. Buduneli et al., in 200624(23 patients), Anne 
Havemose-Poulsen el al., in 200625 (23 patients), and F.B.Mercado et al., in 
200127 (65 patients) showed positive association between periodontitis and 
rheumatoid arthritis in contrast with the results of the study by Fatma Yesim 
Bozkurt et al in 200028(15 patients). In the present study periodontal disease  
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prevalence (Gingivitis 98.9%  &  Periodontitis  74.5%) was  more  in  
rheumatoid  arthritis  patients  than  control patients irrespective of OHI scores  
when compared to other studies. The predominant reason might be the sample 
size (98 patients), In this study prevalence of periodontal diseases was assessed 
based on CPI with LOA and includes wide age group from 15years to 74 years. 
Oral hygiene scores were matched in the present study which plays major role.            
                      
Systemic lupus erythematosus 
                     Tetsuo Kobayashi et al., in 200329 (60 patients) and Ernesto 
Nova et al., in 199930 (30 patients) showed risk of development of 
periodontitis in SLE patients in their study. The present study also revealed the 
same. Prevalence of periodontitis in SLE patients were more in the present 
study (73.3%) than by the study of Ernest Nova et al., (60%)  but same as that 
of with Tetsuo Kobayashi et al (70%).  The possible reason might be the 
sample size. Oral hygiene condition was not matched between case group and 
control group in the study by Ernest Nova et al . 
 
Sjogrens syndrome 
                     Studies conducted by Kuru.B et al in 200232 (8 primary & 10 
secondary sjogrens syndrome patients) and Boutsi et al in 200033 (8 primary &  
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16 secondary sjogrens syndrome patients) showed no difference in periodontal 
status of sjogrens syndrome patients with healthy controls. Jacques Olivier 
Pers et al., in 200531  (15 primary sjogrens syndrome patients)  observed  that  
the  complications  of  periodontitis were not attenuated in sjogrens syndrome 
patients.  In this study among sjogrens syndrome patients prevalence of 
periodontal disease (85.7%) was more than controls irrespective of OHI scores. 
The difference in results might be due to sample size and also due to presence 
of both primary and secondary sjogrens syndrome in previous studies (except 
by Jacques Olivier Pers et al ) which is in contrast with the present study (7 
primary sjogrens syndrome). This study shows less prevalence of sjogrens 
syndrome in this geographic area.     
 
Systemic sclerosis                    
                     G.A.Scardina et al., in 200534 showed the presence of alteration 
in periodontal mucosa microcirculation in 15 systemic sclerosis patients by 
using periodontal capillaroscopy. In the present study prevalence of periodontal 
disease had been observed instead of capillary alterations in systemic sclerosis 
patients and showed more prevalence (Gingivitis – 100% and Periodontits – 
74.1%) 
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Spondyloarthropathy 
                      N.Pischon et al., in 201035 reported that there was 6.81 fold 
increased risk of periodontal disease development in 48 ankylosing spondylitis 
patients. This study also showed similar results that spondyloarthropathy 
patients shows increased risk of periodontal disease development with 
prevalence of gingivitis 100% and periodontitis 77.1% irrespective of oral 
hygiene scores.  
 
Inflammatory myopathies 
                    Krisztina Marton et al., in 200536 could not demonstrated any 
difference in the severity of periodontal destruction between dermatomyositis 
patients and healthy controls while assessing for masticatory force and other 
orofacial abnormalities. The present study showed more prevalence of 
gingivitis (100%) and periodontitis (63.6%) in case group than control 
patients. Study by Krisztina Marton et al., observed patients who were affected 
with hyposalivation and also with minor salivary gland fibrosis. This may be a 
contributing factor in variation of results. 
 
Antiphospholipid syndrome 
                     Schenkein.H.A et al., in 200737 observed only periodontitis 
patients for elevated levels of inflammation markers with high anti cardiolipin  
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which is an antiphospholipid antibodies. It showed positive for the anti-
cardiolipin antibodies. The present study showed all patients had periodontal 
disease but the sample size is too small. The previous study had analyzed 
periodontitis patients rather than antiphospholipid syndrome patients.  Hence it 
needs further evaluation of this rare condition. 
 
Vasculitis                     
                   Haviye Celenligil- Nazliel et al in 199938 evaluated periodontal 
status of patients with Behcet’s disease which is a variant of vasculitis and 
showed more probing depth in them than control patients.  In the present study 
patients with vasculitis have been evaluated for prevalence of periodontal 
disease (Gingivitis – 100% and Periodontitis – 77.8%) and found more than 
control subjects. 
 
Mixed connective tissue disease 
                  There are no studies that evaluated the periodontal status of the 
patients with mixed connective tissue disease without any overlapping 
syndrome. The present study showed periodontal prevalence in all patients with 
mixed connective tissue disease. It needs further evaluation due to small 
sample size . 
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Adult onset still’s disease 
             There are no studies that evaluated the periodontal status of the patients 
with adult onset still’s disease.  In the present study periodontal status of 2 
patients with adult onset still’s disease have been evaluated. (Prevalence of 
gingivitis – 100% and Periodontitis – 50%). The sample size was too small 
which needs further evaluation in this condition about the periodontal disease 
development. 
   
                    In this study among case group it revealed no correlation among 
OHI scores, CPI scores and LOA scores which was in contrast with that of 
control group. Highest score of CPI  prevailed more in case group (Score 4 – 
58.1%) than control group (Score 4 – 2.7%). Score 3 of LOA prevailed only in 
case group (8.7%). These observations denoted prevalence and severity of 
periodontal disease were more in case group than in control group irrespective 
of Oral hygiene scores. 
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SUMMARY AND CONCLUSION 
 
                        Immune mechanism and their effects are similar for both 
systemic autoimmune diseases and periodontal diseases. This study has been 
done to evaluate the periodontal condition of systemic autoimmune diseases. 
253 patients attending the Department of Rheumatology, Government General 
Hospital, Chennai-3 constituted the cases. 262 patients attending the Outpatient 
Department of Tamilnadu Government Dental College & Hospital, Chennai -3 
matched for age, sex and OHI constituted the controls. Oral hygiene status and 
periodontal condition of both cases and controls were assessed using OHI and 
CPI with LOA . Values were analyzed for prevalence of periodontal disease. 
prevalence was more in cases (Gingivitis 99.2% & Periodontitis 73.9%) than 
in controls (Gingivitis 85.5% & Periodontitis 14.9%) considering for age, sex 
and oral hygiene status. 
 
                     Oral hygiene plays an important role in development of 
periodontal disease but the results show that, the prevalence of periodontal 
disease among various systemic autoimmune diseases were irrespective of OHI 
scores. Patients in the case group had more probing depth as well as loss of 
attachment than control group.  
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                     Hence this study showed, systemic autoimmune diseases are 
strongly associated with  periodontal disease. Conversely in patients with 
periodontal disease, but no oral finding, it could be advisable to check for any 
unidentified systemic autoimmune disease.  
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CASE RECORD FORM 
 
OP.NO  : 
 
Date   :       :     :  20 
 
Name   :   Mr / Ms :                                                        
 
Age   :                   Years                                                       
 
Sex  :   Male / Female 
 
Date of birth : 
 
Place of birth : 
 
Address  :  
 
 
 
Phone   : 
 
Occupation  : 
 
Income  :  Rs.                 / Month 
 
Religion  :  Hindu / Muslim / Christian / Jainism / Buddhism / Others  
                                       
 
 
 
Chief complaint   : 
 
 
 
History of presenting illness : 
 
 
 
Medical history   : 
 
 
 
Dental history   : 
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Personal history 
 
a) Number and age of siblings  :   Male      : 
 
                                                                     Female   :      
b) Personal habits  : 
 
                    i)   Smoking   :  
                                
                    ii)  Pan Chewing  :   
 
                    iii) Alcoholism  :   
 
c)    Habits related to oral cavity  : 
 
 i)    Mouth breathing    :    Yes / No 
 
                    ii)   Thumb sucking    :   Yes / No 
 
                    iii) Tongue thrusting    :   Yes / No 
 
                    iv)  Bruxism     :   Yes / No 
 
                    v)   Lip biting/ Nail biting/ Pencil biting :   Yes / No 
                 
 
             d)  Dietary habits   : 
 
 
 
 
General Examination   : 
 
                           i)  Anemia   : 
  
                          ii)  Cyanosis   : 
 
                         iii)  Clubbing   : 
 
                         iv)  Jaundice  : 
 
                         V)  Pedal edema  :  
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Vital signs   : 
 
                         i)   Pulse rate                    : 
 
                         ii)  Respiratory rate          : 
 
                         iii) Temperature               : 
 
                         iv) Blood pressure  :  
 
 
 
Nutritional Status : 
 
                         i)    Height                        : 
 
                         ii)   Weight                       : 
 
                        iii)   Body mass index (BMI)   : 
 
Local Examination : 
 
    a) Extra  oral 
 
                   i) Symmetry                            :  Yes / No 
 
                  ii) TMJ                                
 
1) Mouth opening        : 
 
                              2) Clicking sound :  Present / Not present 
  
                              3)  Pain                        :  Present / Not present 
                                   
                             4)  Tenderness              :  Present / Not present 
 
                             5)  Deviation  :  Present / Not present 
   
              iii)  Lymphadenopathy  : 
 
                             1)   Lymph glands  :  Palpable / Not palpable 
 
  b) Intra oral             
i)  Soft tissue 
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        1)  Labial mucosa  : 
 
        2)  Buccal mucosa  : 
 
                3)  Palatal mucosa  : 
 
                4)  Floor of the mouth  : 
 
                5)  Pillar of fauces  : 
            
                6)  Tongue   : 
 
                7)  Tonsils   :                      
  
ii)  Hard tissue                    
 
        1)  Maxilla                          : 
 
        2)  Mandible                       : 
 
iii) Type of dentition  :  Decidous / Permanent / Mixed 
 
iv)  No: of teeth present : 
 
v)   Missing teeth  : 
 
vi) Dental caries  : 
 
vii)Filled teeth   : 
 
viii) Any prosthesis             :   Removable / Fixed (crown / Bridge)/ 
Complete 
          
         
 
 
         
           ix) Wasting diseases            
 
                      1)  Attrition  : 
 
                      2)  Abrasion  : 
 
                      3)  Erosion  :           
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         x) Enamel Hypoplasia        
 
                     1)  Hereditary            : 
 
                     2)  Environment :   a / b / c / d / e 
 
          xi) Supernumerary teeth       : 
      
         xii) Malocclusion                  :  Angle’s class I /  class II / class III 
 
         xiii) Fractured teeth               :   Yes / No   If yes ,   Ellis class:   
        
         xiv) Deposits                          : 
 
          xv) Mobility   : 
 
 
 
   Gingiva 
 
             a)  Colour   :    
 
             b)  Shape   : 
 
             c)  Contour   : 
 
             d)  Consistency  : 
 
             e)  Surface texture  : 
 
             f)  Bleeding on probing : 
 
             g)  Exudate   : 
 
             h)  Periodontal pocket : 
 
 
 
Provisional Diagnosis   : 
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Investigations     : 
                
               a)  Models  : 
 
               b)  Radiographs : 
 
               c)  Photographs : 
 
               d)  Others  :      
 
 
Treatment   : 
 
 
      I   Emergency phase    : 
 
 
 
     II   Restorative phase    : 
 
 
 
    III   Therapeutic phase   : 
 
 
 
    IV    Preventive phase    : 
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ORAL HYGIENE ASSESSMENT 
1) ORAL HYGIENE INDEX  -  original :  (By Greene & Vermillion in year 1960)  
                                             DEBRIS INDEX  Original 
          Right       Anterior            Left    Total 
 Buccal Lingual Labial Lingual Buccal Lingual  
Upper        
Lower        
 
Debris index              =        (Total of all  scores )                                                                    
                                                    No: of segments scored 
Debris index original  = 
Inference   = 
                                CALCULUS  INDEX  - Original 
          Right       Anterior            Left    Total 
 Buccal Lingual Labial Lingual Buccal Lingual  
Upper        
Lower        
Calculus index  =       ( Total of all scores )                                                                     
                                                   No: of segments scored 
Calculus index original = 
Inference   = 
Oral hygiene index  (OHI) =  Debris index  +  Calculus index 
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CPI  AND LOSS OF ATTACHMENT INDEX 
CPI index 
1) For adults aged 20 years and above 
                                     17         16          11         26         27 
 
 
                                     47         46          31          36         37 
                              2) For subjects aged below 20 years of  
                                                16           11            26 
 
 
                                               46           31             36 
Loss of attachment index 
                             1) For adults aged 20 years and above 
                                     17        16          11          26         27 
 
 
 
                                    47         46          31          36         37 
                              2) For subjects aged below 20 years of 
                                                16           11            26 
 
 
                                               46           31             36 
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            TAMILNADU GOVT. DENTAL COLLEGE & HOSPITAL  
CHENNAI -3 
DEPT. OF PUBLIC HEALTH DENTISTRY         
INFORMED CONSENT FORM  
 
           STUDY TITLE:               
       A case control study to compare the prevalence of periodontal disease in 
patients with and without Systemic autoimmune diseases. 
       
        Name :   Mr/Ms _______________________________    O.P. No.:  
Address:   ____________________________________     SEX   : Male /  
Female 
                        ____________________________________     AGE   :            Years                              
                        ____________________________________ 
                 
I, ________________________, exercising my free power of choice, hereby 
give my consent to be included as a participant in the study . 
 
I agree to the following: 
 
1. I have been informed to my satisfaction about the purpose of the study and    
    study procedures  
2. I understand that the study involves a thorough examination of my oral  
    Cavity for oral health status. 
3. I agree to co-operate fully for complete examination. 
4. I agree to give blood sample or any other body fluid for investigation. 
5. I agree to report to my doctor for a regular follow up as and when required    
    For the research.   
6. I have informed my doctor about all the medications that I am currently  
    taking and other systemic illnesses that I have. 
7. I hereby give permission to use my medical records for research purpose.  
    I am told that the investigating doctor and the institution will keep my  
    identity confidential. 
8. I understand that I have rights to withdraw from the study and also that the  
    investigator has the right to exclude me from the research at any point of  
    time. 
 
 
              Name of Participant              Signature/ Thumb impression                Date: 
 
        
    S.G.Ramesh Kumar 
        Investigator                                                                                       Date: 
S.NO :   
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jkpH;ehL muR gy; kUj;Jtf;fy;Yhhp kw;Wk; 
kUj;Jtkid-brd;id 3 
rKjha gy; ghJfhg;g[ gphpt[ 
Muha@r@rp xg@g[jy@ gotk@ 
Muha@r@rp jiyg@g[ 
gw;g[wjpR neha; kw;Wk; kz;ly jd;Dly; jh';Fjpwd; neha;/ 
,uz;ow;Fk; cs;s bjhlh;gpid Muha;r;rp bra;jy;. 
 
bgau; :jpU_jpUkjp________________             g[w 
nehahspapd; vz; : 
Kftup:     ______________________            ghypdk;  :  
Mz;_bgz; 
                ______________________            taJ :         Mz;Lfs;                          
ehd; ____________________  vd@Dila Raepidt[lDk; kw;Wk; 
KGRje;jpuj;JlDk; vd;id ,k;kUj;Jt Muha@r@rpapy@ 
nru@j@Jf@ bfhs@s xg@g[jy@ mspf@fpnwd@.  
 
1. ,e@j Muha@r@rpapd@ nehf@fk@ kUj;JtKiwfs@ kw;Wk; 
gupnrhjid Kiwfs;  
  Fwpj;j tpsf@f'@fs@ midj@Jk@ vdf@F jpUg@j@jpjUk@ 
tifapy@  
  mspf@fg@gl@ld. 
2. ,e;j Muha;r;rpw;fhf vdJ tha; KG ghpnrhjid bra;ag;gLk; 
vd;gij  
  mwpfpnwd;. 
3. ,e;j Muha;r;rpf;F njitahd KGikahd ghpnrhjidf;F xj;JiHf;f  
  rk;kjpf;fpnwd; 
4. vdJ ,uj;j khjphpfisa[k; kw;Wk; gpw jput';fisa[k; 
ghpnrhjidf;F  
  mspf;f rk;kjpf;fpnwd;. 
5. kUj;Jthpd; Muha;r;rpw;F njitg;gLk;bghGJ kPz;Lk; kUj;Jt 
Ma;tpw;F     
  fz;og;ghf Muha;r;rpahshplk; tu rk;kjpf;fpnwd;. 
6. ehd; Vw;fdnt cl@bfhz@l kw;Wk; cl@bfhs@fpw 
kUe@Jfisg@ gw;wpa  
thpir vz; :  
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  tptu'@fis Muha@r@rpahsuplk@ bjuptpj@Js@nsd@. 
7. ve@j xU epiyapYk@ ehd@ ,e@j Muha@r@rpapypUe@J 
tpyFtjw;Fk@ my@yJ  
  kUj;Jt Muha@r@rpahsUf@F vd@id tpyf@Ftjw;Fk@ KG 
cupik   
    ,Ug@gjhft[k@ mwpfpnwd; 
8. vd; kUj;Jtf; Fwpg;ngLfis ,e@j Muha@r@rpapy@ 
gad@gLj@jpf@bfhs@s  
  rk@kjpf@fpnwd@. ,e@j Muha@r@rp ikaKk@ 
Muha@r@rpahsUk@ vd@Dila  
  tptu'@fs@ midj@ija[k; ,ufrpakhf itg@gjhf mwpfpnwd;. 
9. vdf;F gof;f bjhpahjjhy;/ nkny cs;s midj;ija[k; Twf;nfl;nld;.  
 
  nehahspapd; bgau;       ifbahg@gk@_ ifnuif             njjp   
 
 nr. nfh. ,unk#; Fkhh;         
   Muha@r@rpahsh;                                        njjp 
